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Human enteroviruses (HEVs) are etiological agents of different clinical entities 
varying from asymptomatic to mild, severe, or fatal diseases. There is now 
growing evidence that HEVs can cause or contribute to common chronic 
diseases. Even though a specific therapies are not yet available, a correct 
diagnosis is necessary both for diagnostic and epidemiologic purposes. Gene 
amplification methods and sequencing greatly facilitates the laboratory 
diagnosis of these conditions and allows discovering previously unsuspected 
etiopathogenetic associations. 
In this work, three clinical conditions possibly associated with persistent HEV 
infections have been investigated: type 1 diabetes in children, the post-polio 
syndrome in adult patients, as well as clinical cases of inflammatory 
cardiomyopathy. New methods for HEVs detection have been developed 
based on bioinformatic studies of HEV sequence databases. These methods 
have been tested with reference virus strains as well as a wide range of 
clinical specimens. Our most sensitive assay is based on the detection and 
sequencing of the viral polymerase (3Dpol) coding region. 
Different cohorts of patients have been investigated using classical virology 
and molecular methods. The studies allowed to conclude that HEVs can 
persist for long periods in humans and that these agents can be associated 






1 - Introduction 
Enteroviruses belong to genus Enterovirus of the Picornaviridae family and 
are associated with different human diseases. Enteroviruses were initially 
classified based on neutralization using type-specific antisera and antisera 
pools. Eighty-nine serotypes are identified on the basis of neutralization tests. 
Sixty-six serotypes have been found to be infectious for humans. There are 
both human and non-human species under the Enterovirus genus. Human 
enteroviruses (HEVs) were originally grouped basing on human disease 
manifestations, replication and pathogenesis in newborn mice. 
Although most enterovirus infections are mild and asymptomatic, various fatal 
diseases such as respiratory illness, myocarditis, aseptic meningitis, 
encephalitis and acute flaccid paralysis may occur (Palacios and Oberste, 
2005). Typing of viruses is required primarily to provide information on the 
relationship between virus type and disease, to identify variants with 
increased virulence or specific disease properties, for epidemiological 
investigations, and to allow correlation with viral immunity. New molecular 
technologies have spawned the development of molecular typing methods for 
several virus groups that are not amenable to other means of investigation. 
These methods have recently raised the possibility of simple genotyping 
methods for other virus groups that have been typed traditionally based on 
phenotypic traits. There is growing evidence that HEVs cause or contribute to 
common chronic pathologies, including dilated cardiomyopathy, insulin-
dependent diabetes or type 1 diabetes (T1D), and chronic fatigue syndrome 
(Roivanen and Klingel, 2009). Persistent enterovirus infection has been 
demonstrated both in agammaglobulinemic humans and animals, as well as 
in immunocompetent subjects. A role of the immune system has been 
considered among mechanisms of HEV persistence. Molecular mimicry, 
bystander damage and inflammatory response have been proposed in virus-
induced autoimmune diseases. 
The aim of this study was to investigate the involvement of HEVs in different 





T1D, the post-polio syndrome, and inflammatory cardiomyopathy. In order to 
study these infections characterized by particularly low virus titers, new PCR 
methods based on the region coding for the viral RNA polymerase have been 
developed. These methods are designed to cover almost all known HEV 
types. 
 




2 – The Enterovirus genus 
On the basis of their ability to replicate in human or animal cell types, 
pathogenicity in humans and animals, as well as antigenic differences, the 
Enteroviruses were originally classified into four groups: polioviruses, 
Coxsackie A viruses (CVA), Coxsackie B viruses (CVB), and echoviruses. It 
was quickly realized that there were significant overlaps in the biological 
properties of viruses in the different groups. New enteroviruses isolated are 
after 1970 have been designed by consecutive numbers e.g., EV68, EV69, 
EV70, EV71, etc. (Oberste MS et al., 1999). Recently Enterovirus 
classification has considerably changed. Polioviruses have become part of 
the HEVC species, and Rhinovirus gender has been inserted into the 
enterovirus genus (Table 1). Even though the two classes are quite similar in 
their genomic structure, their clinical manifestations are vastly different. 
Enteroviruses infect the enteric tract, which is reflected in their name. On the 
other hand, rhinoviruses infect primarily the nose and the throat. 
Enteroviruses replicate at 37°C, whereas rhinoviruses grow better at 33-34°C 
(lower temperature of the upper respiratory tract). Enteroviruses are stable 
under acidic conditions and are able to survive exposure to gastric acid. In 
contrast, rhinoviruses are acid-labile (inactivated by low pH conditions). This 
is possibly one reason why rhinovirus infections are restricted to respiratory 
tract. 
 
Table 1 Picornavirus classification (Adapted from the Picornaviridae database 
http://www.picornaviridae.com/; November 2010). 
 
Genus Species Serotypes 
Enterovirus 
Bovine enterovirus 2 types: bovine enterovirus (BEV) 1-2 
Human enterovirus A 21 types including some coxsackie A 
viruses and enteroviruses 
Human enterovirus B 59 types including enteroviruses, 
coxsackie B viruses, echoviruses, and 
swine vesicular disease virus 




Human enterovirus C 19 types including poliovirus (PV) 1-3, 
some coxsackie A viruses and 
enteroviruses 
Human enterovirus D 3 types: EV-68, EV-70, EV-94 
Porcine Enterovirus B 2 types: porcine enterovirus (PEV) 9-10 
Simian Enterovirus A 3 types: simian enterovirus (SEV) V4, 
SV28 and SA4 
Human rhinovirus A 74 types 
Human rhinovirus B 25 types 
Human rhinovirus C 7+ types 
Cardiovirus 
Encephalomyocarditis virus 1 type: encephalomyocarditis virus 
(EMCV). 
Theilovirus 12 types: Theiler's murine 
encephalomyelitis virus (TMEV), Vilyuisk 
human encephalomyelitis virus (VHEV), 
Thera virus (TRV), Saffold virus (SAFV) 
1-9 
Aphthovirus 
Foot-and-mouth disease virus 7 types: O, A, C, Southern African 
Territories (SAT) 1, SAT 2, SAT 3 and 
Asia 1 
Equine rhinitis A virus 1 type: equine rhinitis A virus (ERAV) 
Bovine rhinitis B virus 1 type: bovine rhinitis B virus (BRBV) 
Hepatovirus Hepatitis A virus 1 type: Hepatitis A virus (HAV) 
Parechovirus 
Human parechovirus 14 types: Human parechovirus (HPeV) 1-
14 
Ljungan virus 4 types: Ljungan virus (LV) 1-4 
Erbovirus 
Equine rhinitis B virus 3 types: equine rhinitis B virus (ERBV) 1-
3 
Kobuvirus 
Aichi virus 1 type: Aichi virus (AiV) 
Bovine kobuvirus 1 type: bovine kobuvirus (BKV) 
Teschovirus 
Porcine teschovirus 11 serotypes: porcine teschovirus (PTV) 1 
to 11 
Sapelovirus 
Porcine sapelovirus 1 type: porcine sapelovirus (PSV) 
(formerly PEV-8) 
Simian sapelovirus 3 types: simian sapleovirus (SSV) 1-3 
Avian sapelovirus 1 type: avian sapelovirus (ASV) 




Senecavirus Seneca Valley virus * 1 type: Seneca Valley virus (SVV) 
Tremovirus 
Avian encephalomyelitis virus 1 type: avian encephalomyelitis virus 
(AEV) 
Avihepatovirus 
Duck hepatitis A virus 3 types: duck hepatitis A virus (DHAV) 1-
3 
 
2.1 – Enterovirus structure 
The enterovirus particle consists of a non-enveloped capsid of about 30 nm 
diameter with icosahedral symmetry. The capsid is composed of 60 copies of 
four nonidentical proteins (VP1, VP2, VP3, and VP4), arranged in sixty 
repeating protomeric units of an icosahedron (Figure 1). Even though the 
basic organization of the capsid is shared by all picornaviruses, enteroviruses 
are distinguished on the basis of physical properties, such as buoyant density 
in cesium chloride, and stability at low pH. Many aspects of enteroviral 
pathology, transmission, and general epidemiology are directly related to the 
biophysical properties and their cytolytic life cycle. 
In 1985, the atomic-structure resolution of poliovirus 1 and rhinovirus 14 have 
been reported (Hogle et al.1985; Rossmann et al., 1985) and our 
understanding of Picornaviridae has greatly increased. To date, x-ray 
crystallographic data of more than seven enteroviruses have been obtained 
and interpreted. These studies have included poliovirus 1 (PV1), poliovirus 3 
(PV3) (Filman et al. 1989), HRV3 (Zhao et al. 1993), coxsackievirus B3 
(CVB3) (Muckelbauer et al.1995), bovine enterovirus (BEV) (Smyth et al. 
1995), PV2 (Lentz et al. 1997), coxsackievirus A9 (CVA9), (Hendry et al. 
1999) and HRV16 (Hadfield et al. 1997). All these structures share a 
remarkable degree of overall similarity, while variation is seen on the surface 
and on the inner structures of the capsid. The major capsid proteins VP1 to 
VP3 are each folded into eight-stranded antiparallel β-sheets with a jelly-roll 
topology. These β-barrels of five copies of VP1 are located around the 
fivefold axis, while VP2 and VP3 are around the threefold axis. VP4 is much 
smaller than the other three structural proteins, having a less ordered 
structure, and being located on the inner surface of the capsid, facing the 




RNA. One of the most striking features of Picornavirus surface is the circular 
canyon around the fivefold axis, which has been first seen in human 
rhinovirus 14 (HRV14) (Rossmann et al. 1985). The enterovirus family has a 
deep depression or ‗canyon‘ (12-15 Å depending of the serotype) on the 
capsid surface structure, running around each fivefold vertex. In the inner 
side of the canyon there are conserved amino acid residues involved in the 
attachment to cell receptors (Rossmann et al., 1985). This site is protected 
from the immune surveillance by the inability of neutralizing antibodies to 
penetrate into the canyon (due to their larger size), but can still be accessed 
by cell surface receptors. The canyon is located roughly between VP1 on the 
‘north‘ side (the side closer to the fivefold axis), and VP2/VP3 on the ‗south‘ 
side. This organization leaves five copies of VP1 as a protrusion at the 
fivefold axis. All known enterovirus and rhinovirus structures contain a 
hydrophobic pocket at the base of the canyon, covered by loops of VP1 
(Rossmann et al., 2002). This space is assumed to be normally filled by a 
natural pocket factor, a fatty acid with an aliphatic chain of variable length 
(Figure 2). These pocket factors, including sphingosine (PV1, PV3), palmitate 
(CVB3), and myristic acid (BEV), are believed to be inserted into the virion 
upon release from the infected cell. Binding of the receptor into the canyon 
probably competes with the binding of the pocket factor into the hydrophobic 
pocket. Release of the pocket factor destabilizes the virus and thereby 
initiates uncoating. Replacement of the pocket factor by antiviral compounds 
can inhibit both attachment and uncoating (Salvati et al., 2004).  
Neutralization studies with escape mutants have shown a conserved 
antigenic structure in the HEV capsid organization. Four major epitopes were 
localized, named antigenic sites 1 to 4 (AgS1-AgS4) (Minor, 2004). Antigenic 
site 1 consists chiefly of a continuous sequence of 12 amino acids in VP1, 
together with additional sequences from VP1 in regions around amino acids 
140, 165 and 255 of PV-3. Site 2 is a complex site composed of a continuous 
sequence from VP2, in the region of amino acids 160 to 170, the C terminus 
of VP2 and a short continuous sequence from VP1 in the region of amino 




acid 220. Site 3 consists of several elements from VP3, including residues in 
the region of amino acids 60 and 70, and a sequence from VP1 in the region 
of residues 280 to 290. Site 4, which bridges adjacent pentamers and is 
therefore expressed only on the assembled capsid, includes elements from 
VP3, in the region of amino acids 77 to 80, and VP2, in the region of amino 
acid 72. 
 
2.2 – Enterovirus genome 
Enteroviruses have a small single-stranded RNA genome that is positive 
sense and infectious. The genome, 7.5 kb long, is constituted by a single 
open reading frame flanked by two untranslated regions (UTR) (Figure 3). 
The 5‘UTR region presents a highly folded secondary structure, named IRES 
(internal ribosome entry site) that act as a primer for RNA translation. The 
3‘UTR encodes a cis-acting replication element required for negative strand 
RNA synthesis (Brown et al., 2005). The coding region is translated into a 
single polyprotein of approximately 2,200 amino acids. During the replication 
phase, the polyprotein is processed to generate the four structural proteins 
(VP1 to VP4) and seven nonstructural proteins (2A to 2C and 3A to 3D). The 
four structural proteins are assembled to constitute the icosahedral capsid, 
where are located the neutralizing epitopes. Nonstructural proteins are 
associated with membranous replication complexes and play an essential 
role in virus replication (Teterina et al, 2006). Proteins 2A and 3C are 
proteases, 3D is the RNA-dependent RNA polymerase, 2C is a helicase used 
during RNA encapsidation. Proteins 2B and 3A have been associated with 
various functions in the replication of viral RNA. Protein 3B (VPg) is covalently 
linked to the 5‘UTR region of viral genome and acts as a primer for RNA 
chain initiation and full length RNA synthesis (Pathak et al, 2008). 
An important property of RNA viruses‘ genome is represented by its high 
frequency mutation and recombination rates. RNA replication is extremely 
error-prone, due to the lack of proofreading activity of the viral RNA-
dependent RNA polymerase, taking the error rate to approximately one per 




genome replication (Bouslama et al. 2007). Consequently, enteroviruses exist 
as a dynamic mutant population termed quasispecies, near to a mutational 
meltdown or error catastrophe (Koonin et al, 2008). This high variability within 
RNA virus families acts like an evolutionary force (Domingo et al, 2006). In 
addition, an intratypic and intertypic form of homologous recombination 
between quasispecies ensures adaptability in the environment, contributing to 
viral pathogenesis and to the continuous emerging of new viruses (Arbiza et 
al, 2010). 
 
2.2.1 – The RNA dependent RNA polymerase 
The viral RNA-dependent RNA polymerase (RdRp) coded by the 3D region is 
the core of the replication process. This enzyme is assumed to be an ancient 
protein common to the entire positive-strand RNA virus superclass (Koonin E 
et al., 2008). In early comparative genomic analyses, positive strand RNA 
viruses of eukaryotes were classified into three superfamilies: picorna-like, 
alpha-like and flavi-like. These three superfamilies include most known 
positive-strand RNA viruses. The superfamilies were delineated through a 
combination of phylogenetic analysis of conserved protein sequences, 
primarily those of RdRps, and comparison of diagnostic features of genome 
organization that are linked to replication and expression strategies. In fact, 
comparative analysis of putative RNA polymerases of positive-strand RNA 
agents showed that the polymerase is the only viral protein containing 
conserved motifs through this entire class of viruses (Koonin E, 1993). 
 
2.3 – Enterovirus receptors and cell entry 
Capsid proteins play an important part in receptor binding and, thereby, in 
defining picornaviral tropism and pathogenesis (Rossmann et al., 2002). As a 
vector of the infecting genome, the capsid is exposed to the extracellular 
environment. In particular, the VP1 capsid protein plays an important role as 
the major protagonist in the virion-cell interplay. Therefore, it contains most of 
the epitopes involved in cell entry. As shown in Table 2, picornaviruses 




exploit several different surface molecules as receptors, including 
immunoglobulin-like molecules and adhesion proteins. 
 
Table 2. Summary of enterovirus receptors. 
Serotype Receptor Coreceptor References 
IgSF receptors 






Coxsackievirus A9 αvβ3 integrin Integrin Berinstein et 
al., 1995 
Echoviruses 1, 8 α2β1-Integrin (VIa-2) Integrin Bergelson et 
al., 1992 
Major group HRV (90 
serotypes)  
ICAM-1  Bella et al.m 
1998 
Coxsackieviruses B1-B6 CAR lg-like  
Other receptor types 
Coxsackievirus A21 DAF (CD55) SCR-like 
(complement 
cascade) 








DAF (CD55) SCR-like 
(complement 
cascade) 
Echoviruses 3, 6, 7, 11-
13, 20, 21, 24, 29, 33 
DAF (CD55) SCR-like 
(complement 
cascade) 




Minor group HRV (10 
serotypes) 
LDL-R  Hewat et al., 
2000 
Abbreviations: PVR, poliovirus receptor; DAF, decay-accelerating factor; CAR, 
coxsackievirus-adenovirus receptor; ICAM, intercellular adhesion molecule; IgSF, 
Immunoglobulin super family; LDL-R, low-density lipoprotein receptor. 





Different types of cell surface molecules serve as cellular receptors for 
picornaviruses, and some are shared among picornaviruses and members of 
other virus families. For some enteroviruses (e.g., poliovirus), a single type of 
receptor is sufficient for entry of viruses into cells. For other viruses, a second 
molecule, or coreceptor, is needed for virus entry into cells. For example, 
coxsackievirus A21, which binds to CD55, requires also the intercellular 
adhesion molecule 1 (ICAM-1) for entry into cells (Figure 4). 
Most of the enterovirus cell receptors belong to the immunoglobulin 
superfamily domains (IgSF). These molecules usually consist of tandem 
repeats of between two and five Ig-like domains: the amino-terminal domains 
D1 interact with viruses, whereas their carboxy-terminal terminus consists of 
a transmembrane and a short cytoplasmic region. Besides, the canyon offers 
another advantage for receptor attachment, namely that the binding of the 
receptor triggers the uncoating process. When the receptor is bound to the 
capsid canyon, the virion becomes unstable and is ready for the 
internalization. 
There are, however, other molecules that do not belong to the Ig superfamily, 
used as enterovirus receptors. These molecules bind outside the capsid 
canyon and are called low-density lipoprotein receptors (LDL-R) (Hofer et al., 
1994). The minor-group HRV serotype use the very-low-density lipoprotein 
receptor (VLDL-R), whereas some of the HEVA and HEVB group serotypes 
use the DAF (CD55) receptor. VLDL-R binds north of the canyon close to the 
icosahedral fivefold vertex, whereas DAF binds south of the canyon around 
the icosahedral twofold axes (Shafren et al., 1997). These receptors do not 
cause viral instability upon binding. Thus do not, by themselves, trigger 
uncoating. However, their recruitment can trigger the aggregation of other 
receptor molecules or they could trigger endocytosis followed by lowering of 
pH in endosomal vesicles (for instance, FMDV; Carrillo et al., 1984). 
The next step of cell infection is the cell entry. Depending on the receptor 
type and attachment site, there seems to be different mechanisms of cell 




entry. The interaction of the virion with receptor initiates major structural 
changes in the particle, leading to release of the genome. The resulting 
particles (called altered, or A-particles), have lost the internal capsid protein 
VP4. In addition, the N-terminus of VP1 is exposed outside of the canyon, on 
the surface of the A-particle (Fricks CE and Hogle JM, 1990). In this entry 
method, the A-particle has an increased affinity for membranes because of 
the VP1 hydrophobic exposed sequence. A gap is formed on the virion 
surface, in the area where VP1, VP2 and VP3 meet, allowing the emergence 
of VP4 and the N-terminus of VP1. With this conformation, the N-termini of 
VP1 can insert into the plasma membrane. A pore is formed and the RNA is 
released into the cytoplasm. 
Some enteroviruses (e.g., rhinovirus) enter cells by receptor-mediated 
endocytosis. Uncoating may be triggered by acidification of the endosomal, 
pH-dependent pathway. Infection of cells by these viruses is inhibited by 
weak bases and ionophores that block the acidification of endosomes (Knipe 
et al., 1997). For these viruses, interaction with a cell receptor serves only to 
concentrate virus on the cell surface. The virion-receptor interaction does not 
induce uncoating-related changes in the virus particle, but rather serves only 
to tether the virus to the cell and bring it into the endocytic pathway. 
 
2.5 – Enterovirus life cycle 
Once the viral RNA is in the cytoplasm, viral replication begins. The first step 
in this phase is viral RNA translation, because it cannot be copied by any 
cellular RNA polymerase and the virion is devoid of endogenous enzymes 
(Figure 5). In fact, there‘s no 5‘ capping on the viral genome, nor viral 
enzymes in the capsid. The 5‘ untranslated region contains a highly-folded 
RNA secondary structure, capable to bind to the 40S ribosomal subunit (Jang 
et al., 1988). 
The viral RNA is translated by the cellular machinery into a single, long 
polyprotein. During the translation phase, when the ribosomes are attached 
and the polyprotein is produced, the translation's product is cleaved by virus-




encoded proteinases. This strategy allows solving the mRNA polycistronic 
limitation in viral replication, enabling the synthesis of multiple protein 
products from a single RNA genome. 
Enterovirus genome encodes two proteinases: 2Apro and 3Cpro (or 3CDpro), 
which carry out cleavage of the polyprotein. The cleavage process occurs in 
two phases. The primary cleavage between P1 and P2 is mediated by 2Apro. 
Several cellular proteins are cleaved by 2Apro, including eIF4GI, eIF4GII, 
Pabp, and heart muscle dystrophin (Glaser and Skern, 2000; Kundu et al., 
2005). In the same time, 3CPro cleaves between P2 and P3. An intermediate 
cleavage produces both 3Cpro and 3CDpro proteinases, which have different 
activities. 3CDpro is released from the P3 precursor by autocatalytic cleavage 
and is capable to carry out secondary cleavage of glutamine-glycine 
dipeptides in P1 intermediate more efficiently that 3Cpro. All the primary 
cleavages occurs in cis, while after the proteinases have been released, they 
cleave the polyprotein in trans. During the secondary cleavages, all the viral 
proteins are produced. Both 3Cpro and 3CDpro process proteins of the P2 and 
P3 regions with similar efficiency. The viral 3D protein works like a RNA 
dependent RNA polymerase. The RNA polymerase 3Dpol is produced by 
cleavage of a precursor protein, 3CDpro, which is highly active as a proteinase 
but has no polymerase activity. 
The same RNA molecule that has been used in translation, is then used as a 
template for synthesis of negative-stranded RNA molecules by the virus-
encoded polymerase. These strands are then used in synthesizing large 
amounts of positive-stranded copies that are used in translation of viral 
proteins, as well as being encapsidated into assembling particles. 
At the end of the infectious process, capsid proteins are synthesized and 
assembled into immature subunits, containing VP1, VP3 and VP0, which at 
the final stage of virion assembly is cleaved into VP2 and VP4. Infectious 
virus particles are produced in one infected cell that is finally destroyed 
allowing the viruses to be released and infect new target cells. Empty capsids 
(defective) are common in the Picornavirus life cycle. 




A single infected cell can typically produce 104 to 105 virus particles that are 
released by lysis of the cell. The lysis has been proposed to occur due to 
increased permeability of cell membranes, which results from increasing 
concentrations of nonstructural proteins 3A and 3AB (Lacal, Carrasco., Lama 
& Carrasco 1992), 2BC (Aldabe et al. 1997), and 2B (van Kuppeveld et al. 
1997). The production of viral proteins (especially 2A and 2B) inhibits the 
cellular proteins secretion, even in absence of the viral RNA replication 
(Doedens and Kirkegaard, 1995). 
 
2.6 – Clinical diseases 
Enteroviruses are present in the environment and vehicles for their 
dissemination include stools, skin lesions, nasal and bronchial secretions. 
They can be isolated both from the upper and lower alimentary tract and can 
be transmitted by the fecal-oral and respiratory routes. Fecal-oral 
transmission is the primary mode of spread, especially in poor sanity 
conditions: contaminated water and wastewater represent the main sources 
of this virus (Ali et al., 2003). Clinical outcome ranges from unapparent 
infection to severe and life threatening disease. Enteroviruses that cause a 
vesicular exanthem (like FMDV, CVA-10, 16, 8; EV-71) presumably can be 
spread by direct or indirect contact with vesicular fluid, which contains 
infectious virus. 
In particular, EVs are among the most commonly identified etiologies of 
myocarditis, causing between 25 and 35% of cases for which an etiology is 
found (Martino et al., 1994). Neonates and young infants are particularly 
susceptible to EV myocarditis, but most cases occur in young adults between 
the age of 20 and 39 years. 
Meningitis is a frequent manifestation of EV infection which, in turn, is the 
most common cause of meningitis in the US. The severity of EV meningitis 
varies with host age and immune status (Rotbart et al., 1997). EV 
Encephalitis is well documented, but relatively uncommon (Tyler, 2009) and 
generally linked to immunodeficiency diseases. Unlike aseptic meningitis, 




which may have prolonged morbidity but from which recovery is generally the 
rule, encephalitis due to the EV may have long-term sequelae. 
Neonatal infection with EVs poses the greatest risk for severe disease when 
illness develops in the first days of life; this pattern suggests possible 
transplacental acquisition (Hawkes and Vaudry, 2005). Mortality is typically 
due to hepatic failure or myocarditis. 
By the end of the 70s, CVBs has been implicated as an etiologic agents of 
various diseases, both acute (i.e. myocarditis, aseptic meningitis, pancreatitis) 
and chronic (i.e. dilated cardiomyopathy, insulin dependent diabetes mellitus, 
chronic meningoencephalitis). Nowadays there are no vaccines against non-
polio enteroviruses and treatment of infection is only symptomatic. 
 
Table 3. Clinical syndromes associated with infections by enteroviruses. 
Polioviruses, types 1-3 
Paralysis (complete to slight muscle weakness) 
Aseptic meningitis 
Undifferentiated febrile illness, particularly during the summer 
Coxsackieviruses group A, types 1-24 
Herpangina 




Hand-foot-and mouth disease (A10, A16) 




Acute hemorrhagic conjunctivitis (type A24 variant) 




Severe systemic infection in infants, meningoencephalitis, and myocarditis 





Upper respiratory illness and pneumonia 
Rash 
Hepatitis 
Undifferentiated febrile illness 
Echoviruses, types 1-33 
Aseptic meningitis 
Paralysis 
Encephalitis, ataxia, or Guillan-Barré syndrome 
Exanthema 
Respiratory disease 
Others: diarrhea, epidemic myalgia, pericarditis, myocarditis, hepatic disturbance 
Enterovirus, types 68-71 
Pneumonia and brionchiolitis 
Acute hemorrhagic conjunctivitis (type 70) 
Paralysis (types 70-71) 
Meningoencephalitis (types 70-71) 
Hand-foot-and-mouth-disease (type 71) 




2.7 – Figures 
 
Figure 1. Poliovirus capsid structure. 
 
Electronic micrograph of negatively stained poliovirus (left). Diagram of the virion, showing 
the location of capsidic protein and genomic RNA (right). The capsid consist of 60 structural 
units, each made up of a single copy of VP1, VP2, VP3, and VP4, arranged in 12 pentamers. 
 
Figure 2. Enterovirus capsidic pocket factor. 
 
All known enterovirus structures contain a hydrophobic pocket at the base of the canyon, 
covered by loops of VP1 normally filled by a natural pocket factor, a fatty acid with an 
aliphatic chain of variable length. Binding of the receptor into the canyon probably competes 
with the binding of the pocket factor into the hydrophobic pocket. Release of the pocket factor 
destabilizes the virus and thereby initiates uncoating. 




Figure 3. Enterovirus genome organization. 
 
The genome is a positive stranded RNA particle and has a single ORF that encodes a polyprotein precursor. The ORF is flanked by two 
untranslated regions. The polyprotein is cleaved during translation by two virus-encoded proteases to produce structural and non-structural 
proteins. The P1 protein is cleaved into the virion capsid proteins, while the P2 and P3 proteins are cleaved to form the proteases and the 
proteins that participate in viral RNA synthesis. 
 




Figure 4. Cell receptors for Picornaviridae. 
 
A schematic diagram of the cell proteins that function as receptors for different picornaviruses 
is shown. The different domains (Ig-like, short consensus repeat-like [SCR-like], low-density 
lipoprotein-like [LDL-like], and threonine/serine/proline [T/S/P] are labeled. CAR, 
coxsackievirus and adenovirus receptor; PVR, Poliovirus receptor; ICAM-1, intercellular 
adhesion molecule-1; VCAM-1, vascular cell adhesion molecule 1; CD55 or DAF, Decay 
Accelerating Factor; LDLR, low-density lipoprotein receptor. 




Figure 5. Enterovirus life cycle. 
 
The viral RNA is translated by the cellular machinery into a single, long polyprotein. 






), which carry out 
cleavage of the polyprotein. The cleavage process occurs in two phases. The primary 
cleavage between P1 and P2 - mediated by 2A
pro
 – and the secondary cleavage of P2 and 
P3 proteins. Several cellular proteins are cleaved by 2A
pro
, including eIF4GI, eIF4GII, Pabp, 
and heart muscle dystrophin. The same RNA molecule that has been used in translation, is 
then used as a template for synthesis of negative-stranded RNA molecules by the virus-
encoded polymerase. At the end of the infectious process, capsid proteins are synthesized 
and assembled into immature subunits. 
 




3 – Persistent enterovirus infections 
To establish persistent infection, a virus must be able to reduce its cytopathic 
effects (i.e., its ability to kill or damage the infected cell), maintain its genome 
within host cells over time, and avoid elimination by the host immune system. 
In vitro, persistent PV infection has been studied in neuroblastoma cells 
(Gosselin et al., 2003) and cultured fetal neuronal cells (Pavio et al., 1996). 
Persistence is a rather common event in enteroviral infections. In vitro, human 
glomerular mesangial and vascular endothelial cells may support chronic 
enteroviral infection; in vivo, coxsackievirus infection has been documented in 
endomyocardial biopsies of individuals progressing from viral myocarditis to 
dilated cardiomyopathy. In vitro, persistence is associated to cellular secretion 
of a variety of cytokines and growth factors that modulate cell behavior (e.g., 
motility, adhesion, proliferation) and stimulate the inflammatory response 
(Zanone et al., 2003). Nowadays, it is becoming evident that these viruses 
can be implicated in several chronic illnesses (Roivanen and Klingel, 2009) 
including juvenile onset diabetes mellitus, chronic fatigue syndrome, 
dermatomyositis and polymyositis, congenital hydrocephalus, amyotrophic 
lateral sclerosis. Persistent EV infections occur most often in 
agammaglobulinemic patients; a common clinical manifestation is 
represented by meningoencephalitis (McKinney et al., 1987); half patients 
with persistent EV meningoencephalitis have concomitant dermatomyositis or 
polymyositis. These observations confirm the important role of antibody in EV 
clearance, an unusual phenomenon because many other viruses are 
contained largely by cell-mediated immunity. 
There have also been reports demonstrating persistence of enterovirus or the 
enterovirus genome in immunocompetent humans and animals with several 
diseases, including chronic dilated myocardiopathy, inflammatory muscle 
disease (myositis), and diabetes. 
Although the B- and T-cell response in enterovirus infections has a role in 
virus clearance, there are indications that it may also lead to disease. There 




are several reasons for considering a role for immunopathology in some 
enterovirus-induced diseases: 
a. The enterovirus-induced diseases are inflammatory in nature; 
b. The experimental animal models for enterovirus-induced diseases 
demonstrate the importance of genetic susceptibility in their causation, 
and the efficacy of treatment with immunosuppressive drugs; 
c. The enterovirus-induced diseases are related to human diseases that 
are considered to have an autoimmune contribution. An immune-
mediated disease process has been vigorously proposed in the case 
of enterovirus-induced chronic dilated cardiomyopathy, chronic 
myositis, and diabetes. 
A role for both molecular mimicry and bystander damage has been proposed 
in virus-induced autoimmune disease. In the former, an immune response 
directed against the virus cross-reacts with a cellular protein and causes 
disease. In the case of bystander damage, a virus up-regulates nonspecific 
immune responses that lead to pathology. Recent data regarding 
coxsackievirus-induced T1D and coxsackievirus-induced myocarditis suggest 
the importance of bystander damage rather than molecular mimicry (Fujinami 
et al., 2006). The presence of proinflammatory cytokines would then activate 
Th1 cells or macrophages that foster immunopathology. Once damage 
occurs, new cellular epitopes that are not normally exposed and that are 
antigenic may trigger additional reactive epitopes, a process called epitope 
spreading. 
 
3.1 – Type 1 Diabetes 
T1D is a particular form of diabetes mellitus due to the loss of pancreatic beta 
cells and to the consequent deficit of insulin production. Classical symptoms 
are polyuria (frequent urination), polydipsia (increased thirst), polyphagia 
(increased hunger), and weight loss. T1D is a chronic immune-mediated 
disease with a sublinical prodromic period of variable duration, which follows 
a defective function or a selective and massive destruction (80–90%) of β-




cells (Notkins, 2002). The progression of the autoimmune process is slow, 
with a highly variable duration. Selective β-cells distruction may take from a 
few months to several years, before the eventual presentation of overt 
disease. The subclinical phase is characterized by the circulation of 
autoantibodies targeting β-cells. There are several disease-related 
autoantibodies that have shown to predict clinical T1D, the most important 
are: insulin autoantibodies (IAAs), the 65kDa GAD isoform autoantibodies 
(GAD65), the transmembrane protein tyrosine phosphatase (TPT)-related IA-
2 molecule, and the Zinc transporter 8 protein autoantibodies (ZnT8). 
GAD65 is encoded by a gene on chromosome 10p11. It is expressed in 
neuroendocrine cells, including pancreatic islets, and is located within 
neuron-like small vesicles. However, the function of GAD65 in the islets is not 
known. Between 60 and 80% of newly diagnosed T1D patients have 
autoantibodies to GAD65. These antibodies are directed primarily to the 
middle and C-terminal portions of the molecule and recognize conformational 
epitopes. The second major autoantigen, IA-2 (or ICA512), is encoded by a 
gene on chromosome 2q35. Because of a critical amino acid replacement at 
position 911 (Asp for Ala), IA-2 is catalytically inactive. IA-2 is a 
transmembrane protein found in the secretory vesicles of both endocrine and 
neuronal cells that seems to play a role in insulin secretion (Saeki et al., 
2002). Nearly the same percentage (60–70%) of newly diagnosed T1D 
patients have autoantibodies against IA-2 and GAD. These autoantibodies 
are directed exclusively to the intracellular domain of IA-2 and recognize 
primarily conformational epitopes. The third major autoantigen is insulin. This 
protein is only 51 amino acids in length, and its gene is on chromosome 
11p15. As with IA-2 and GAD65, the majority of autoantibodies recognize 
conformational epitopes, mainly on the B chain of insulin. Autoantibodies 
against insulin are among the first autoantibodies to appear in the prediabetic 
state and are usually found in very young children. Between 30 and 50% of 
children with T1D have autoantibodies against insulin (Atkinson and 
Eisenbarth, 2001). 




Individuals must be genetically predisposed to develop T1D. The most 
important genes contributing to disease susceptibility are located in the HLA 
class II locus on the short arm of chromosome 6 (Pociot et al., 2010). 
Nevertheless, only a small amount of genetically susceptible individuals - less 
than 5% - progress to clinical disease, and the concordance range is only 30-
50% between monozygotic twins (Redondo et al., 1999). This implies that 
additional factors are needed to trigger and drive cell destruction in 
genetically predisposed subjects. It is thus strongly suspected that 
environmental factors play a role in the pathogenesis of the disease in 
genetically characterized subset of the population. The surprising increase in 
T1D incidence during recent decades, its incidence variation from one 
country to another and seasonality are factors that lead to the hypothesis of 
viral involvement in this pathology. Besides rubella virus, mumps virus, 
cytomegalovirus, retroviruses and rotaviruses, the most suspected viruses 
are enteroviruses, especially CVB4 (Goldberg and Krause, 2009). 
 
3.1.1 – Enteroviruses and T1D 
There are many studies that suggest a possible association of T1D disease 
with enterovirus infections. Many of these are based on serological data, 
including some studies on virus isolation or detection in pancreas autopsy 
samples. In recent years, the introduction and development of the molecular 
methods have opened up many new possibilities to assess the role of viral 
infections. 
Studies undertaken in several countries showed that anti-enterovirus 
antibodies as well as enterovirus RNA are found more frequently in the blood 
of recently diagnosed diabetic patients than in healthy controls. 
 
Table 4. Detection of EVs in T1D patients. 
Country Patients Sample No. Patients Positive Controls Reference 
France Children & 
Adults 
Plasma 39 50 0 Chehadeh 
et al., 2000  






Serum 49 22 2 Lönnrot M 
et al., 2000 
Sweden Children PBMC 24 46 29 Yin et al., 
2002 
Australia Children Plasma 206 30 4 Craig ME et 
al., 2003 
Japan Children Serum 61 38 3 Kawashima 
H et al., 
2004 
Germany Children Serum 47 36 4 Moya-Suri 
et al., 2005 
Norway Children Feces 113 51,3 - Witsø E et 
al., 2006 
Finland Children & 
Adults 
Intestine 12 9 10 Oikarinen 
et al., 2007 
 
3.1.2 – Possible mechanisms of HEV pathogenesis in T1D 
There are several mechanisms, not mutually exclusive, through which 
enteroviruses can play a role in β-cells destruction and T1D onset. 
 Pancreas and β-cells infection: Various enterovirus serotypes can 
infect and replicate in human islets in vivo as well as in vitro. This can 
results in β-cells destruction (Klemola et al., 2008) which induces the 
production of cytokines (like IFN-α, β). This event stimulates the 
expression of molecules (like IL-15 and ICAM-1) that intervene in the 
pathogenic processes. The assumption that enteroviruses cause β-cell 
cytolysis is supported by observations describing the presence of viral 
antigens in human β-cells as well as the destruction of islet cells in 
patients deceased from systemic enterovirus infections (Ujevich et al., 
1980). The presence of enterovirus RNA and/or of infectious virus, 
especially CVB4, in pancreatic islets of T1D patients was also reported 
(for literature, see Table 4Error! Reference source not found.). 
 Persistence of enteroviruses: Enteroviruses are able to establish 
persistent infections, a characteristic that can contribute or trigger the 




chains of events that lead to T1D. A particular CVB4 strain has been 
characterized. It is able to establish persistent infections in human 
pancreatic islet cells in vitro (Frisk and Diderholm, 2000) due to a 
series of mutation on the canyon portion of the VP1 capsid protein. 
There are several possible mechanisms that can induce β-cells 
destruction by persistent infection. EV infection can disturb the release 
of insulin in response to high glucose levels. A persistent infection can 
result in the induction of an autoimmune response directed towards β-
cells through presentation of viral antigens and self antigens to T 
lymphocytes and activation of the immune system (Hyöty and Taylor, 
2002). Enterovirus infections, and re-infections can initiate or 
accelerate β-cell impairment through the activation of anti-enteroviral T 
lymphocytes which, by cross-reactivity, participate in aggravation of the 
impairment of β-cells persistently infected by another enterovirus 
serotype (Hyöty and Taylor, 2002). The local inflammatory reaction 
which accompanies the persistent viral replication can also take part in 
recruitment of autoreactive cytotoxic T lymphocytes (CTL) in the islets. 
The infection of β-cells causes an inflammation which provokes cell 
damages and release of sequestered antigens. Through bystander cell 
activation, the local inflammation results in recruitment and activation 
of autoreactive T lymphocytes directed against these self-antigens 
(Horwitz et al., 2002). 
 Enteroviruses and molecular mimicry: A partial sequence homology 
(i.e., molecular mimicry) has been detected between enteroviral 
proteins and β-cell self-antigens: 1) 2C viral protease and the GAD65; 
2) VP1 viral capsid protein (plus the VP0 precursor) and IAR/IA-2 
protein on one hand and the HSP60 protein on the other hand. In a 
mouse model designed for testing molecular mimicry between P2C 
and GAD65, the infection with CVB4 did not accelerate diabetes. 
However serum collected from patients with an enterovirus infection 
can react with IA-2/IAR (Harkonen et al., 2003). 




 Antibody-mediated enhancement of enterovirus infection: Non-
neutralizing CVB4 antibodies are able to enhance the replication of 
CVB4 in monocytes/macrophages, and hence the CVB4-induced IFN-
α production by these cells (Hober et al., 2002). The enhancing effect 
was higher with plasma or IgG from patients with T1D than from 
healthy individuals and it was higher with peripheral blood cells from 
patients, due to IgG bound to their cells (Chehadeh et al., 2005). The 
target protein of antibodies that increased the CVB4-induced IFN-α 
production by PBMCs and CVB4 infection of PBMCs was identified as 
the capsid protein VP4, which indicates that this protein is accessible 
to antibodies at physiological temperatures. The levels and the 
prevalence of anti-VP4 antibodies were significantly higher in patients 
with T1D than in healthy subjects (Sauter et al., 2008). The antibody-
dependent enhancement of CVB4 infection of circulating blood cells 
could play a role in virus dissemination in the host, and consequently 
in the pathogenesis of diseases induced by this virus. 
 Enteroviruses and thymus: T1D is an autoimmune disease that is the 
result of a defect in tolerance towards β-cell antigens at the peripheral 
level through anomalies of regulatory T lymphocytes (Treg) and/or at 
the central level through disturbances of thymus functions. It has been 
hypothesized that the infection of thymus by an enterovirus could 
disturb thymic function thus playing a role in T1D pathogenesis. In the 
human system in vitro, CVB4 replicates and persists in human thymic 
epithelial cells and infects human fetal thymus fragments, resulting in 
disturbances of T lymphocyte maturation (Brilot et al., 2002). In the 
mouse system, CVB4 can infect the thymus in vivo and, in vitro, it 
replicates in thymic cell primary cultures and in fetal thymus organ 
cultures, resulting in a disturbance of the maturation/differentiation of T 
lymphocytes (Jaïdane et al., 2006). The possibility that virus-induced 
disturbances of thymus play a role in the pathogenesis of T1D can thus 
be taken into consideration. 





3.3 – Post polio syndrome (PPS) 
After the acute episode, polio survivors experience a period of neurological 
and functional recovery, followed by a phase of almost complete stability 
(Farbu et al., 2006). Since 1980, there has been an increasing acceptance of 
PPS. The condition may develop 15 to 40 years after acute paralytic and 
nonparalytic disease in 20 to 78% of polio survivors. (Trojan and Cashman, 
2005). Common manifestations include generalized, central and peripheral 
fatigue, muscle weakness, musculoskeletal pain, and new disabilities that 
sometimes involve the respiratory and the alimentary tracts. Worldwide, there 
are over 20 million polio survivors, thus PPS represents the most prevalent 
motor neuron disease today (www.post-polio.org). In spite of the numbers of 
affected patients, the etiology and pathogenesis of this syndrome are obscure 
and no effective therapy is available (Farbu et al., 2006). Current treatments 
are based on a conservative approach consisting of exercise, avoidance of 
muscular overuse, orthoses, and assistive devices. Diagnosis is based on 
medical history and clinical-instrumental examination, since no specific 
biomarkers are available. A number of hypotheses have been proposed to 
explain the pathological changes associated with PPS. The most granted 
conjecture is the distal degeneration hypothesis (Wiechers and Hubbell, 
1981) (Figure 6). In a normal subject‘s spinal cord, a single anterior horn 
motor neuron does innervate numerous skeletal muscle myofibers (e.g., 200 
to 4,000 myofibers per neuron). When PV infects motor neurons, the cells are 
killed and do not regenerate. As a consequence of axonal degeneration, 
innervation of myofibers is lost and paralytic disease ensues. This event 
marks the onset of paralytic poliomyelitis. After the acute episode, during a 
period of several years, a neurogical and functional recovery occurs. This 
phenomenon is attributed to a compensatory axonal sprouting of residual 
anterior horn motor neurons, which markedly increases the number of muscle 
fibers innervated by residual motor neurons in the affected area. Extreme 
enlargement occurs in these motor units, reaching 7-8 times the normal 




innervation ratio of individual motor neurons. Functional stability goes on for 
8-35 years, with little variation in strength and physical performance. After 
years of stability, the late effects of polio develop and are interpreted as due 
to the degeneration of axonal sprouts in the enlarged motor units and /or to 
the loss of entire motor units. 
Different factors may contribute to the distal degeneration years after the 
acute episode: 
 Aging, overuse myopathy and disuse muscular atrophy. With the 
normal aging process, the physiological loss of motor neuron is 
particularly felt in patients with reduced physical activity. Overuse 
contributes to skeletal muscles weakness in partially denerved 
muscles (Gordon et al., 2004). Disuse is associated in normal 
individuals with muscular isotropy and weakness (Thomas and 
Zijdewind, 2006). 
 Autoimmune reaction. No motor unit antibodies have been detected in 
PPS patients. 
 Viral infections. A viral persistent infection in the central nervous 
system is plausible. Persistent infections have been observed in 
animal models and cell cultures, as well as immunocompromised 
patients. Muscular biopsy of PPS patients reveals small perivascular 
and perimisial lymphocytic infiltrates. This observation led to the 
chronic myositis hypothesis (Dalakas et al., 1986). The presence of 
lymphocytic infiltrates, loss of neurons and gliosis has been observed 
in deceased PPS patients (Kaminski et al., 1995). Finally, some 
studies report the intrathecal production of anti-PV antibody as a sign 
of active intrathecal infection (Sharief et al., 1991). This observation 
has not been confirmed (Julien et al., 1999). 
 
3.3.1 – Viral persistence in PPS patients 




In support of a persisting PV infection, several authors have detected portions 
of PV genomes in cerebrospinal fluid (CSF) samples taken from PPS 
patients, with a prevalence of positives ranging from 10% to 65% in different 
studies. Sequencing of amplified fragments allowed the presumptive 
identification of the three PV serotypes in different patients. In few cases, the 
presence of different enterovirus serotypes has been reported. 
So far, serum and muscle tissue samples were consistently negative for PV 
infection. Mononuclear cells of the peripheral blood resulted positive in seven 
patients out of 37 (19%). Taken together, the above results report the 
possibility of persisting PV genome fragments in the CNS of PPS patients. 
These data do not clarify the role of genome fragments in PPS pathology. 
It has been suggested that the presence of the viral genome in CSF is a 
purely random event and there is no link between viral persistence and 
pathological effects on neuronal cells. However, no PV genomic fragments 
were found in CSF of control patients (Julien et al., 1999; Muir et al., 1995; 
Leon-Monzon and Dalakas, 1995; Leparc-Goffart et al., 1996; personal data). 
It is hypothesized that the persistence of the genome of PV in the CNS can 
cause a chronic inflammatory response and pathologic changes determined 
by cytotoxic or immune-mediated damage. Moreover, in PPS, as well as in 
other degenerative motor neurons pathologies, there is a decrease in the 
expression of neurotrophic factors (Goodall et al., 2006; Pun et al., 2006). 
At present, however there are no reliable data that allow correlating the 
persistence of genomic sequences of PV with the typical symptoms of PPS. 
It‘s possible that viral persistence is established in the early stage of the 
disease and the viral sequences remain present at low levels in the "stable 
phase". 
 




Table 5. PV detection in previous studies. 
PPS Patients Controls 
Bibliography 
# Sample Positives Region Serotype PPS Other 
24 CSF 3 (12,5%) 5‘UTR CVB-1,4 0/24 0/36 
Muir P et al., 
1995 
Serum 0 (0%) - 0/24 0/36 
7 Bone 
marrow 
3 (42,8%) CVB-4 - - 
Cerebral 
cortex 
0 (0%) - - - 










0 (0%) 5‘UTR - - 0/5 
7 (18,9%) 3Dpol - - 0/5 
10 Muscular 0 (0%) 5‘UTR - - - 
10 CSF 5 (50%) 5‘UTR PV-1,2,3 0/23 2/23 Leparc-
Goffart I et al., 
1996 
5 (50%) VP1 - 0/23 0/23 
20 CSF 13 (65%) 5‘UTR PV-1,2,3 3/7 0/20 
Julien J et al., 
1999 
11 (55%) VP1 - 0/7 0/20 
VP1-2° - 0/7 0/20 
 
3.2 – Viral cardiomyopathy 
Myocarditis is a clinical condition characterized by infiltration of the heart via 
inflammatory cells. There can be considerable destruction to the heart tissue, 
which in a significant number of patients may lead to persisting cardiac 
abnormalities or death. Idiopathic dilated cardiomyopathy (DCM) may also 
occur as a late consequence of myocarditis. DCM is a pathologic process 
characterized grossly by dilatation and contraction of impaired ventricles. 
Histologically shows a marked myocyte hypertrophy with myocytes containing 
large bizarre nuclei, extensive interstitial fibrosis, focal replacement fibrosis, 
and endocardial thickening (Richardson et al., 1996). It is an end-stage 
process and has no known etiology. However, many investigators favor the 




possibility that DCM may represent a sequelae of acute viral myocarditis, 
either caused by persistence of virus or as a result of an autoimmune 
phenomenon secondary to previous exposure to virus. Evidence in favor of 
this hypothesis includes the presence of foci of inflammatory cells in DCM, 
the difficulty in both the clinical and pathologic distinction between DCM and 
acute myocarditis, and the documented presence of HEVs genome fragments 
(Satoh at al., 2007) and proteins (Zhang et al., 2004). Since enteroviruses are 
thought to be one of the most common causes of acute myocarditis, several 
groups have sought evidence of these viruses in DCM. 
 
Table 6. Investigated causes of cardiomyopathy 
Viral causes of cardiomyopathy Non-viral causes of cardiomyopathy 
Adenovirus, Arbovirus, Arenavirus, 
Coxsackie virus Epstein—Barr 
virus, Echovirus, 
Encephalomyocarditis Virus, 
Hepatitis C, Human herpesvirus 6, 
Human immunodeficiency, virus-1 
and 2, Human and avian, influenza 
viruses, Mumps virus, Parvovirus 
B19, Poliomyelitis virus, Rabies 
Respiratory syncytial, virus, Rubella 
virus, Rubeola virus, Vaccinia virus, 
Varicella virus, Variola virus 
Bacterial: Brucellosis, Clostridia, Diphtheria, 
Francisella, Cytomegalovirus, Gonococcus, 
Haemophilus, Legionella, Meningococcus, 
Mycobacterium, Mycoplasma, Pneumococcus, 
Psittacosis, Salmonella, Staphylococcus, 
Streptococcus, Tropheryma whippleii, Rickettsia, 
Borrelia, Leptospira, Syphilis, Typhus 
Fungal: Actinomyces, Aspergillus, Blastomyces, 
Candida, Coccidioides, Cryptococcus, Histoplasma, 
Nocardia, Sporothrix 
Helminthic: Cysticercus, Echinococcus, 
Schistosoma, Toxocara, Trichinella 
Protozoal: Entamoeba, Leishmania, Trypanosoma, 
Toxoplasmosis 
 
3.2.1 – Hypothesized viral cardiomyopathy mechanism 
In order to understand the viral cardiomyopathy pathologic mechanism, acute 
myocarditis course have to be explained. Myocarditis is usually viewed as a 
chronological sequence of three pathologically distinct phases that occur after 




the virus comes into contact with the cardiac myocyte (Yajima and Knowlton, 
2009). During the first phase, direct destruction of the cardiomyocytes occurs 
by virus-mediated lysis causing degradation of cell structures, which in turn 
facilitates entry of the virus into the cells with consequential myocyte injury 
and cardiac dilatation. This initial phase frequently passes unnoticed since 
the initial damage is often prevented by the innate immune response. The 
second phase develops as a result of immune dysregulation triggered by the 
initial cardiomyocyte injury. The initial cellular and humoral immune 
responses may improve the outcome during phase 1; conversely, they are 
responsible for the harmful effect during phase 2. In addition, some host 
myocardial cellular antigens can share epitopic similarities (molecular 
mimicry) with viral antigens, and can therefore induce an autoimmune trait 
that can sustain the inflammatory response and hence the chronic 
inflammation phase (Feldman and McNamara, 2000). Finally, in the third 
phase, the pathological signs of myocarditis generally disappear and the 
destroyed myocytes are replaced by diffuse fibrosis. A typical picture of 
dilated cardiomyopathy develops as a result of extensive myocardial injury. 
Evolutive biventricular dilatation with cardiac failure can be observed, which 
has been linked to a persistent virus or latent endomyocardial replication 
(Andréoletti et al., 2000). 
While the pathological changes seen in acute myocarditis are compatible with 
injury caused as a consequence of infection with a lytic virus and the immune 
response following such infection, the structural alterations required at cellular 
level to cause DCM are more difficult to interpret in the context of a viral 
disease. Immune mediated damage to the heart as a mechanism of 
pathogenesis for viral cardiomyopathy is at present speculative. The 
interaction between persistent infection and immune response to the agent 
may cause sufficient cellular damage to initiate disease. Experimental studies 
in mice have shown that different components of the immune system play a 
role in the survival of the infected animals. Mice lacking CD4 positive cells are 
more likely to develop myocarditis but those without functional T cytotoxic 




cells survive longer (Henke et al., 1995) and are less likely to develop 
myocarditis. Which component of the immune response is most active during 
a low grade infection in man and against which viral proteins is at present 
unknown. 




3.4 – Figures 
 
Figure 6. Distal degeneration Hypotesis. 
 
A) When PV infects motor neurons, the cells are killed and do not regenerate. B) As a 
consequence of axonal degeneration, innervation of myofibers is lost and paralytic disease 
ensues. C) After the acute episode, a neurogical and functional recovery occurs. This 
phenomenon is attributed to a compensatory axonal sprouting of residual anterior horn motor 
neurons. D) After years of stability, the late effects of polio develop and are interpreted as 
due to the degeneration of axonal sprouts in the enlarged motor units and /or to the loss of 
entire motor units. 
 









4 - Enterovirus diagnosis 
Serotype identification is an important aspect of Enterovirus diagnosis both 
for a scientific and clinical aspect. Serotype identification and sub-grouping of 
viruses can provide the framework for a better understanding of the biological 
properties of the agents thus defined. For clinical diagnosis it is often 
sufficient to establish a diagnosis of ―enterovirus infection‖ without further 
investigations. However, in certain situations serotype identification can 
provide a reliable basis for medically significant differentiation which will 
provide clinical guidance in particular syndromes (e.g., hemorrhagic 
conjunctivitis, acute paralytic disease) and contribute to epidemiological 
knowledge and disease prevention (e.g., the recent HEV71 epidemic in Asia).  
Prior to the molecular era, monoclonal antibodies and oligonucleotide 
fingerprinting were used to analyze serotype variations. These approaches 
were limited by their inability to show small differences among similar agents. 
Neither technique was able to readily detect any patterns among seemingly 
unrelated virus isolates. The introduction of molecular techniques, in 
particular genomic sequencing, has significantly enriched the tools available 
to epidemiologists and taxonomists .By analyzing the random mutations that 
occur in the genome of different EVs, closely related viruses were easily 
detected and, in addition, more distantly related viruses were clustered into 
distinct phylogenetic groups. Molecular epidemiologic studies have been 
applied to the poliovirus global eradication program. These studies were able 
to determinate the relations between isolates of different geographic areas, 
the infection trend and the recombination of vaccine strains with a variety of 
EVs (Nathanson N, Kew OM, 2010). 
 
4.1 - Biological approach 
The classical gold standard for virus identification is to isolate the virus in cell 
culture followed by neutralization test using pooled and monospecific 
antisera. It was shown that Enteroviruses can be propagated using several 





2, WI-38 cell lines; Terletskaia-Ladwig et al., 2008). At present, there is no 
universal protocol on the optimal combination and number of cell lines 
required for enterovirus isolation, and different combinations are used in 
different laboratories. Virus isolation by cell culture may be affected by a 
number of factors. The physiological conditions of cells and whether blind 
passages are performed is an important aspect. Blind passages are important 
when the initial virus titer is extremely low and cytopathic effect is not 
apparent (Lipson et al., 1988). The evolution of the classical culture assay is 
the shell vial-assay and low speed centrifugation. This method is able to 
shorten detection time and enhance viral recovery (Gleaves et al., 1984). 
Neutralization tests using pooled antisera can give objective serotype 
identification. 
 
4.1.1 – Determination of neutralizing antibodies 
In neutralization assays, virus suspension (100 PFU) is incubated with 
antibodies of known viral specificity. After incubation for 1 hour, the mixture is 
inoculated into susceptible cell cultures. Cell cultures are observed for 
evidence of viral cytopathic effect (CPE) for 5 to 7 days. CPE indicates that 
the antibodies failed to neutralize the virus. Conversely, lack of CPE indicates 
that virus was neutralized by one of the employed the antibody. This is a 
cumbersome procedure that requires determining the titer of the virus prior to 
the start of the procedure and a lengthy incubation after inoculation of cell 
cultures with the mixture of antibody and virus-infected cells. Although 
neutralization testing may be used in identifying all types of viruses, it is used 
only when more rapid methods are not available. 
Equine type-specific sera have been mixed to give pools containing different 
combination of individual antisera. Enterovirus isolates are incubated with 
each pool and reinoculated onto susceptible cell lines. From the neutralization 
pattern, the virus serotype can be inferred. The most famous intersecting pool 
is the Lim Benyesh-Melnick (LBM) pool scheme, divided into eight pools (A-





recently updated with seven new pools against 19 serotypes (J-P) (Bendig 
and Earl, 2005). Cell culture isolation and serotyping using neutralization 
tests are accurate but have several disadvantages. They are expensive 
(Rigonan, 1998) and time-consuming since virus isolation may take up to 3 
weeks‘ time and neutralization test can takes one week to give results. Cell 
culture isolation has a relatively low sensitivity and neutralization can be 
hindered by virus aggregation, antigenic drifts or presence of multiple viruses 
in clinical specimens (Muir et al., 1998). 
 
Table 7. Susceptible EV cell lines. 
Cell line Organism Type Receptor EV susceptibility 
HEL Homo sapiens Fibroblast CAR, 
CD155 
Coxsackie viruses A, 
ECHO viruses 3-6-7-9-11-
12-27; PV 1,2,3; 
KB Homo sapiens Epithelial CAR, DAF, 
CD155 
PV 1,2,3; ECHO viruses 3-
6-7-9-11-12-27; Coxsackie 
viruses A9-B1-2-3 
MRC-5 Homo sapiens Fibroblast ICAM-1, 
DAF 
Rhinovirus (major group); 
Coxsackie viruses A, B 




PV 1,2,3; ECHO viruses 3-
6-7-9-11-12-27; Coxsackie 
viruses A9-B1-2-3 
RD Homo sapiens Fibroblast DAF PV 1, enterovirus and 
Coxsackie A virus 
CaCo-2 Homo sapiens Epithelial DAF ECHO viruses 3-6-7-9-11-
12-27, Coxsackie B virus 
RMK Rheus Monkey Epithelial CAR, 
CD155 
PV 1,2,3; ECHO viruses 3-
6-7-9-11-12-27; Coxsackie 
viruses A9-B1-2-3 
SF Homo sapiens Fibroblast DAF Coxsackie viruses A, B 
DAF-BGMK African green 
monkey 
Epithelial CAR, DAF ECHO viruses 3-6-7-9-11-
12-27, Coxsackie A virus 
,Coxsackie B virus 






A549 Homo sapiens Epithelial CAR Coxsackie viruses A9-B1-2-
3 




HeLa Homo sapiens Epithelial DAF,CD15
5 
PV-1,2,3 
AV3 Homo sapiens Epithelial CD155 PV 1,2,3 
WI-38 Homo sapiens Fibroblast CAR, 
CD155 
PV 1,2,3 Coxsackie viruses 
A9-B1-2-3 
Abbreviations: HEL, human embryonic lung fibroblasts; KB, human epidermoid carcinoma 
cells; MRC-5, human diploid fibroblasts; PRMK, primary rhesus monkey kidney; BGMK, 
buffalo green monkey kidney; RD, embryonic rhabdomyosarcoma; CaCo-2, colonic 
carcinoma; RMK, rhesus monkey kidney; SF, human fetal foreskin cells; DAF-BGM, 
genetically engineered BGM expressing human decay-accelerating factor; AV3, cervical 
adenocarcinoma; WI-38, Wistar Institute cell line 38. 
 
4.1.2 – ELISA for enterovirus antibodies 
Various Enzyme Linked Immunosorbent Assay (ELISA) have been designed 
for enterovirus serotyping. ELISA can be used for indirect diagnosis, can be 
simply automated, and may be effective in the investigation of outbreaks. 
ELISA methods that test for homotypical antibodies are impractical unless 
there is a clinical suspicion of the presence of one particular serotype, 
whereas heterotypical antibody assays allow detection of most enterovirus 
serotypes (Craig et al., 2003). Compared with classical methods ELISA assay 
are sensitive and specific for laboratory diagnosis (Bendig, 1996), but they 
have some limitations. The need to prepare large quantities of purified virions 
and interacting with secondary anti-human IgM in the ELISA assay made the 
method an expensive, laborious and lengthy process. In addition, since the 
whole virus is used as the capture antigen in the ELISA assay, cross-
reactions with antibodies against other enteroviruses could results in false 
positives. Thus, the specificity of the IgM-based ELISA may be compromised 






4.1.3 – Immunofluorescence for enterovirus antibodies 
Another conventional method used by the majority of laboratories is indirect 
immunofluorescence (IIF) assay. The cells are scraped from the infected 
monolayer and placed on a microscope slide. The preparation is fixed then 
flooded with MAbs of known specificity. Binding of MAbs to viral proteins is 
signaled by the presence of fluorescence when the preparation is viewed 
using the fluorescence microscope. The type of fluorescence (e.g., speckled 
versus confluent) and the location of the fluorescence in the cell (e.g., 
cytoplasmic vs. nuclear) are useful in differentiating viruses. This process 
takes only 1 to 2 h and overall gives a sensitive and specific viral 
identification. This method does not require the time-consuming neutralization 
test, but it still needs to isolate and propagate the virus. Since virus isolation 
involves a long time, it still hinders the progress of diagnosis. In addition, 
monoclonal antibodies are usually raised against the VP1 protein of prototype 
strains that may not be able to recognize mutant viruses in clinical specimens. 
Unfortunately, IF staining cannot be used to definitively identify all viruses. 
Examples of this are the coxsackieviruses, polioviruses, and echoviruses of 
the enterovirus group, which are closely related and have numerous 
serotypes. In some cases, these may be identified as to their sub-group by IF. 
However, the MAbs for enteroviral identification have been shown to lack 
sensitivity (Klespies et al., 2996), cross-react with rhinoviruses, and usually 






Table 8. Advantages and disadvantages of various virus detection approaches. 
Method Advanced Disadvantages 
Cell Culture Isolate wide variety of viruses (including unanticipated agents); 
provide isolate for additional studies: antiviral susceptibility testing, 
serotyping, and epidemiologic studies; increased sensitivity over 
rapid antigen tests 
Technical expertise needed to read CPE; long 
incubation period for some viruses, need for 
purchasing/ maintaining a variety of cell culture 
types in-house 
Neutralization Provide isolate for additional studies and epidemiologic studies; 
increased sensitivity over rapid antigen tests. Impartial serotypic 
identification. 
Long and impracticable job, extremelly expensive. 
Poor sensibility and false-positives cases. 
Immuno 
fluorescence 
Generally good sensitivity (which varies with virus detected); 
excellent specificity; CMV antigenemia is more sensitive than 
traditional or shell vial cultures for CMV in blood 
Generally not as sensitive as cell cultures; 
requires expertise in reading; not useful for all 
viruses; adenovirus sensitivity especially poor 
ELISA Can be used for indirect diagnosis, can be simply automated. 
Sensitive and specific for laboratory diagnosis. 
Need to prepare large quantities of purified 
virions. False positives due to cross-reactions with 
antibodies against other enteroviruses. 
Molecular Methods Excellent sensitivity and specificity; short turnaround with real-time 
PCR; useful for viruses that cannot be cultured in traditional cell 
cultures 
Technical expertise required for developing and 
standardizing methods; expensive due to costs of 






4.2 - Molecular approach 
Development of polymerase chain reaction (PCR) greatly facilitates 
enterovirus diagnosis, becoming a common practice for viral identification in 
diagnostic laboratories. The establishment of informatics databases of 
published enterovirus genome sequences has allowed highly conserved 
sequences to be identified. These have been exploited as primer recognition 
sequences for reverse transcriptase PCR (RT-PCR) assays capable of 
detecting most or all enteroviruses, including those that cannot readily be 
propagated in cell culture as well as untypable isolates (Chapman et al., 1990 
Hyypiä et al., 1989). It is also possible to detect enterovirus RNA by RT-PCR 
in specimens from which infectious virus is never or only rarely recovered by 
culture, such as myocardial tissue from patients with acute myocarditis or 
dilated cardiomyopathy (Baboonian and Treasure, 1997) and in formalin-
fixed, paraffin-embedded tissue. As compared to traditional methods, viral 
nucleic acid detection is fast, sensitive and reliable. Different regions of the 
genome have different functions and the rate of their evolution reflects this 
condition. The noncoding regions contain sequences that are recognized by 
the host cell ribosomal subunits as well as by factors playing a role in the 
replication of the genome. These specific motifs are highly conserved. On the 
other hand, the external capsid proteins are subjected to the pressure caused 
by host antibodies and exhibit notable variation in length and sequence of the 
loop structures connecting the beta-sheets. This is evidently the reason why 
more than 100 different serotypes exist among HEVs. Nonstructural proteins 
have important functions in the life cycle of the virus and many of these 
polypeptides are highly conserved. 
Since PCR technique introduction into clinical diagnosis, a plethora of 
molecular methods for enterovirus identification has been developed. These 
methods can be classified on the basis of the target region. 
 





Due to the nature of Enterovirus genome, PCR primers for Enterovirus 
detection were firstly designed basing on the highly conserved enteroviruses 
5‘UTR region (Rotbart, 1990; Zoll, 1992). Pan-enterovirus primers were able 
to detect virtually all types of enteroviruses. 
Comparison of the 5‘UTR human enteroviruses nucleotide sequences has 
shown two main clusters with a minimum identity of 75% within each cluster 
(Figure 8 A). This high conservation is due to the need of maintaining the 
secondary structure, essential for the translation initiation (stem-loop 
structure). The nucleotide sequence variation seen in this region of all 
sequenced enteroviruses shows mainly compensatory base changes that 
support the proposed stem-loop structures. The 5‘UTR can be divided into 
conserved (nucleotides 1 to 650, PV1 reference strain CHAT) and hyper 
variable regions (nucleotides 651 to 750) according to the nucleotide variation 
(Toyoda et al., 1984).  
However, due to the lack of variation in the amplicon, 5‘UTR-based methods 
can‘t provide serotype-specific information. Besides, 5‘UTR sequences are of 
limited utility for molecular typing because no reliable correlation exists 
between 5‘UTR sequence and serotype (Kubo et al., 2002). 
 
4.2.2 - Capsid amplification methods 
The P1 region of the enterovirus genome encodes four structural proteins 
(VP4, VP2, VP3 and VP1) which form the viral capsid (Figure 8 B). While VP4 
is completely internalized in the infectious virion, the others are partially 
exposed on the virus surface. Escape mutants studies of EVs serotypes with 
neutralizing monoclonal antibodies had permitted to identify a number of 
neutralization determinants located on the three exposed viral proteins 
(Minor, 1992). Sequence analysis of the ‗neutralizing‘ regions can be used to 
determine the virus serotype. Therefore, numerous RT-PCR assays have 
been developed that utilize oligonucleotide primers that anneal to sequences 
encoding the capsid proteins. However, primer design is crucial: primers must 





VP4 region has been used with some success in a recent study from Japan, 
but is likely to suffer limitations (Ishiko et al., 2002). It is not exposed on the 
virion surface, therefore it doesn‘t feel the selective pressure and can‘t 
discriminate between different serotypes The VP2 region sequence was 
shown to poorly correlate with serotype since expected branch points were 
not observed when phylogenetic trees were constructed (Oberste et al., 
1998). 
The VP1 region has been used extensively for molecular typing of 
enteroviruses. The sequence of the VP1 region has been documented to 
highly correlate with serotype due to the large number of neutralization sites 
present on the VP1 surface. Often these assays utilize highly degenerated 
oligonucleotide primer sets that contain wobbles and deoxyinosine residues. 
These primer modifications allow the primer to tolerate some variations in 
target sequence. Subsequently, these primers are capable of amplifying 
many different serotypes. The deoxyinosine residues will bind to any 
nucleotide, but reaction kinetics involved lead to decreased sensitivity 
(Oberste et al., 1999), especially for clinical specimens. Thus, it is often 
difficult to obtain sequentiable amplicons. Most VP1 assays still require that 
an enterovirus be cultured in order to obtain virus concentrations significantly 
higher than those present in clinical specimens, giving rise to the same 






4.3 – Figures 
 
Figure 8. HEV molecular trees. A) 5‘UTR region. B) P1 region. C) 3D region. 
 






5 - Methods 
 
5.1 – Sample preparation 
In this work different biological samples were used. Depending on the 
specimen, different approaches were employed: 
 Liquor samples 
Direct PCR  
 Whole blood sample 
Leukocyte separation with Sigma HISTOPAQUE-1119 and 
HISTOPAQUE-1077 and co-culture with cell lines (HeLa, AV3, HpL 
3.4). 
 Tissue sample 
Mechanic and enzymatic dissociation of primary cell for cell culture. 
 
5.2 - Cell Culture and reference HEV types 
Different EV susceptible cell types were cultivated in order to amplify the viral 
titer and observe a cytopatic effect. HeLa, AV3, CaCo-2 and RD cell lines 
were obtained from American Type Culture Collection (Promochem, 
Teddington, UK). Cultures of HeLa and AV3 cells were co-cultivated with 
5x105 peripheral blood total leukocytes obtained from patients or healthy 
controls and incubated at 37°C in a humidified atmosphere with 5% CO2. To 
enhance the efficiency of interaction, lipofectamine was added to the medium. 
After five serial passages, cell supernatant was collected, clarified by low-
speed centrifugation, aliquoted and frozen at –70°C (Figure 9). All the viral 
serotypes were obtained from American Type Culture Collection 
(Promochem, Teddington, UK). For a complete list, see Table 9. Viral stocks 
were prepared by infecting confluent HeLa monolayers using a multiplicity of 
infection (m.o.i.) = 3.0. Fifteen hours post-infection (p.i.), the supernatant was 
collected, clarified by low-speed centrifugation, aliquoted and frozen at –





96-well plates. CPE was read on day 5 p.i. Virus titers were expressed as 
Tissue Culture Infectious Doses 50/ml (TCID50/ml). 
Table 9. Reference HEV serotypes. 
Genus Species Serotype Source 
Enterovirus 
Human Enterovirus A 
CVA16 ATCC 
CVA2 NIH * 
Human Enterovirus B 
CVB2 Ohio ATCC VR-29 
CVB4 JVB ATCC VR-184 
CVB6 Schmitt ATCC VR-155 
CVA9 Griggs NIH * 
E12 NIH * 
Human Enterovirus C 
CVA24 DN-19 ATCC VR-1662 
CVA19 Dohi ATCC VR-177 
PV1 Chat ATCC VR-1562 
PV2 Sabin NIH * 
PV3 Leon ATCC VR-62 
Human Enterovirus D EV94 NIH * 
* National Institute for Health and Welfare (NIH), Helsinki. Thanks to Dr. Merya Roivainen. 
 
5.3 - Indirect immunofluorescence (IIF) for capsid antigen detection 
Cells infected with leukocytes of different patients were stained by IIF with 
EVs/PVs monoclonal antibodies (mAbs) in order to detect the expression of 
cytoplasmic viral antigens. Infected cell monolayers in 2-well chamber slides 
(Nalgene-Nunc, International PBI, Milano, Italy) were fixed with 
paraformaldehyde, washed in PBS containing 1% FCS, permeabilized with 
Triton X100 (0.05% in PBS, 10 min), briefly immersed in distilled water, and 
dried out. Different mAbs to capsid enterovirus antigens were used: 
 
Table 10. Antibody table. 
Antibody Subclasses Specificity 





Poliovirus blend IgG1 & IgG2a PV-1,-2,-3 
Poliovirus 1 IgG1 PV-1 
CVB4-356.1 IgG1 CVB4 
 
Rabbit FITC-labeled antibody to total mouse IgG (Sigma) was used as 
secondary antibody, upon dilution with Blue Evans in PBS. Slides were 
examined with a fluorescence microscope (BX-60; Olympus, Tokyo, Japan) 
equipped with a digital camera. 
 
5.4 - Separation of peripheral blood leukocyte 
In order to isolate and extract peripheral blood cell type(s), flow cytometry and 
cell sorting methods were used to identify and separate leukocyte 
subpopulations. Total leukocytes were obtained by centrifugation on 
Histopaque gradients (1.199 and 1.077 g/ml).  
 
Table 11. Pheripheral blood leukocytes separation protocol. 
Step Action 
1 Place 4ml of whole blood into a 15ml Falcon tube 




2 Centrifuge for 30 minutes @ 1500 rpm. 
3 Place the two formed leukocytes rings into a new 
15ml Falcon with 10ml DMEM F12 HAM + 5% 
FBS,r Sample 
collection 4 Centrifuge for 5 minutes @ 1500 rpm, suspend the 
pellet in FBS + 10% DMSO, count and freeze first 
at -20°C for 15 minutes, then at -80°C 
 
5.5 – Tissue extraction 
Tissue samples were first processed with FastPrep-24 automatic 





lyse the entire material. Samples were added to impact-resistant 2.0 ml tubes 
containing an optimized lysing matrix for RNA extraction and water. 
Instrument causes the lysing matrix particles to impact the sample from all 
directions simultaneously, releasing nucleic acids and proteins into the water. 
After centrifugation of the sample, normal viral RNA extraction method 
follows. 
 
Table 12. Tissue extraction protocol. 
Step Action 
1 Cut approximately 3mm of tissue sample and 
place into Green Matrix tubes with 1ml RNAse, 
DNAse free water. 
Preparation 
2 Insert the sample in FastPrep-24 and run the cycle 
for 40s @ 6.5m/s. 
Lysis 
3 Follow the normal Viral RNA extraction protocol Extraction 
 
5.6 – Viral RNA extraction 
Viral RNA was extracted from liquid samples (0.5-1.0 ml) using the Promega 
DNA and RNA extraction kits (Promega, Madison, WI) in the automated 
extractor Abbott M2000sp. The system makes use of magnetic particles for 
RNA purification. When amounts of sample <0.5 ml were available, the 
QIAMP Viral RNA minikit (Qiagen, Valencia, CA) was used. Viral RNA binds 
specifically to the vials silica membrane while contaminants pass through. 
PCR inhibitors such as divalent cations and proteins were removed in two 
wash steps with proprietary buffers, leaving pure RNA to be eluted in DNAse- 
and RNAse-free water. The original protocol has been optimized for low viral 
RNA concentrations. 
 
Table 13. Viral RNA extraction protocol. 
Step Action 





AVL buffer, 5.6μL of RNA carrier and 140 μL of 
sample. Vortex and spin for 15 seconds and 
incubate for 10 minutes @ room temperature. 
2 Briefly centrifuge to eliminate drops inside of the 
lid. Add 560 μL of absolute ethanol (96%-100%). 
Spin for 15 seconds. 
3 Briefly centrifuge to eliminate drops inside of the 
lid. Add 630 μL of the resulting solution into a 
QIAamp Mini spin column. Centrifugate for 1 
minute @ 8000 rpm and discard the eluate. 
Membrane 
binding 
4 Repeat the step 3 four times. 
5 Add 500 μL of AW1 buffer and centrifuge for 1 
minute @ 8000 rpm. Discard the eluate. 
Washing 
6 Add 500 μL of AW2 buffer and centrifuge for 3 
minutes @ 14000 rpm. Discard the eluate. 
7 Centrifuge for 1 minute @ 14000 rpm. Discard the 
elute and put the column into a 1.5ml eppendorf 
tube. 
8 Add 50 μL of AVE buffer and centrifugate for 1 
minute @ 8000 rpm. 
Final elution 
 
5.7 - Viral RNA extraction from paraffin embedded specimens 
Paraffin blocks were treated to extract viral RNA. In the initial phase, paraffin 
blocks were sectioned and deparaffinated. Afterward normal protocol for RNA 
extraction from tissues was performed with the QIAMP Viral RNA minikit 
(Qiagen, Valencia, CA). 
 
Table 14. Viral RNA extraction from paraffin embedded specimens 
Step Action 





paraffin with a scalpel. Microtome blade was 
cleaned with acetone to eliminate contaminating 
RNase. 2 x 10 µm sections are cut and placed in a 
1.5 ml eppendorf tube. 
2 Excess of paraffin is removed from each section 
with a clean scrape. Add 1 ml xylene to the sample 
and incubate for 20 minutes @ RT with agitation. 
Wash 3 times with 1 ml 100% ethanol for 3 
minutes @ RT with agitation, air-dry samples 
under a hood. 
Deparaffinization 
3 Normal tissue extraction protocol followed RNA extraction 
 
5.8 – RNA retrotranscription 
After extraction, RNA was retrotranscribed with random hexamer primers. 
The retro transcription process was carried out by the SuperScript® VILO 
cDNA synthesis kit (Invitrogen, Carlsbad, California). The original protocol 
has been slightly modified to improve sensitivity. 
 
Table 15. . Viral RNA retrotranscription protocol. 
Step Action 
1 Combine the following components in a 0.2ml 
tube on ice. 
 5X VILO™ Reaction Mix 4 µl  
 10X SuperScript® Enzyme Mix 2 µl  
 RNA (up to 2.5 µg) 12 µl  
 DEPC-treated water 2 µl  
Gently mix tube contents. 
Mix preparation 
2 Set the thermocycler at: 
 25°C for 10 minutes 






 85°C for 5 minutes 
 4°C ∞ 
 
5.9 – Primer design 
Reference strains sequences where chosen according to the prototype 
strains listed on the Picornaviridae database (www.picornaviridae.com). All 
sequenced EV serotypes were aligned for every analyzed region utilizing 
CLCbio Genome Workbench. Human Parechovirus (HPeVs) serotypes were 
used as an outgroup. Successively, alignments were analyzed with the 
MEGA package (Kumar et al., 2008) and a phylogenetic tree was drawn for 
every aligned region. A Neighbor Join algorithm was chosen for the tree 
prediction and a boostrap of 1,000 for statistical analysis. The complete tree 
was then analyzed and divided into subtrees. Every subtree was separately 
realigned and analyzed with the COMPASSS suite for searching conserved 
motifs (Maccari et al., 2010). The designed primers were analyzed for dimers, 
hairpins, annealing temperature with the NetPrimer software (Premier biosoft, 
www.premierbiosoft.com). 
In the PPS study, an original three-primer pairs method targeted at the 3D 
(RNApol) region was designed. This novel highly sensitive primer set is 
composed of a 5 primers. This set has been developed on the basis of a pan-
polio primer set originally composed of only 2 primers and unable to 
discriminate PV types. 
For other studies, potentially involving all non-polio HEVs, a general HEV 
PCR-detection method has been designed targeting the 3D region. Based on 
a complete alignment of over 90 HEV types, a phylogenetic tree was drawn 
and a 7-group serotype subdivision has been defined. 
For all studies, RT-PCR methods targeting the 5`UTR region have also been 
used. Published (Hyypiä et al., 1989; Halonen et al., 1995; Yang et al., 1992) 
primer sets have been employed together with an original primer set 





Molecular typing of different HEVs has also been attempted by using an 
original real time protocol developed at the American CDC (Nix et al., 2006). 
 
Table 16. 5'UTR primers. 
Name Sequence Reference 
PanEntero F CCCCTGAATGCGGCTAAT 
Personal data 
PanEntero R GATTGTCACCATAAGCAGCCA 
Hyypia F CATTCAGGGGCCGGAGGA Hyypiä et al., 
1989 Hyypia R AAGCACTTCTGTTTCC 
EV/PCR1 (F) ATTGTCACCATAAGCAGCCA Halonen et 
al., 1995 EV/PCR2 (R) TCCTCCGGCCCCCTGAATGCG 
EV/PCR3 (F) ACACGGACACCCAAAGTAGTCGGTTCC Yang et al., 
1992 
 
5.10 – PCR amplification 
The retrotranscribed RNA was amplified by PCR (or real-time PCR) with 
primers directed to the 5`UTR, VP1, and 3D genome regions. Real time 
assays were performed on the ABI Prism 7000 real-time PCR thermocycler, 
and end-point PCR assays were performed on the Verity thermocycler 
(Applied Biosystems, Foster City, CA) as well as the peqSTAR 96 universal 
gradient cycler (PeqLab, Wimington, DE). 
 
Table 17. PCR protocol. 
Step Action 
1 Combine the following elements into a 0.2 ml tube: 
 GeneAmp 10X PCR Buffer II (without MgCl2) 5 
µl 
 dNTP Mix 1.25 mM 5 µl 
 MgCl2 1.5 mM 4 µl 







 Primers 10 µM 1 µl each 
 DMSO 2 µl 
 Molecular biology pure water 24.5 µl 
 cDNA 5 µl 
2 Set the thermocycler at: 
 95°C for 10 minutes 
 45-step cycle: 
95°C for 30 seconds 
58°C for 1 minute 
70°C for 2 minutes 
 70°C for 15 minutes 
 Store at 4°C 
PCR cycle 
 
For the real-time PCR, reaction was performed using the Sybr green system 
(Applied Biosystems) in 50 ml final volume. Real-time data were collected 
during extension steps. Serial dilutions of genomic RNA extracted from a 
CVB-4 stock containing 2x106 TCID50/ml were used as a quantitative 
reference for viral genome amplification. The threshold cycle number (Ct 
value) represents the cycle number at which fluorescence signals significantly 
different from the baseline were obtained. 
 
Table 18. Real-time PCR protocol. 
Step Action 
1 Combine the following elements into a 96-wells 
microplate: 
 SYBR® Green PCR Master Mix 
 500 nM of each primer,  
 Molecular biology pure water ‗till a final volume 
of 50 µl 
Sample 
preparation 





 95°C for 10 minutes 
 40-step cycle: 
95°C for 15 seconds 
60°C for 30 seconds 
72°C for 30 seconds 
 Real-time data are collected during extension 
steps. 
 
5.11 – PCR purification 
After amplification, positive PCR products were purified. Where the 
amplification product was poor and/or smeared, a 2% agarose gel in Tris 
borate EDTA (TBE) buffer was loaded with the total PCR product. The gel 
band was then cleaved and purified. 
The liquid phase PCR product purification was carried out by the ExoSAP-IT 
(USB, Cleveland, OH) method, a single step enzymatic cleanup of PCR 
products that eliminates unincorporated primers and dNTPs. 
 
Table 19. Liquid phase PCR product purification. 
Step Action 
1 Place 1 µl of ExoSAP-IT for each 2,5 µl of PCR 
product into a 0.2 ml tube. 
Sample 
preparation 
2 Set the thermocycler at: 
 37°C for 15 minutes 
 80°C for 15 minutes 
Clean up reaction 
 
cDNA recovery from agarose gel was carried out by TaKaRa RECOCHIP 
(TAKARA Bio Inc., Tokio, Japan), a disposable chip designed to recover DNA 







Table 20. Agarose gel PCR purification. 
Step Action 
1 Push the gel cutter into the agarose gel on the 
anode (+) side near the DNA band to create a gap. 
Wet the RECOCHIP in electrophoresis buffer and 
push it into the gap, black surface faces toward the 
DNA band. Start electrophoresis. 
Preparation 
2 Run electrophoresis until the entire band is into the 
RECOCHIP. Remove the RECOCHIP and 
centrifuge 5 seconds @ 5000 rpm into a 2 ml tube. 




5.12 – Amplicon sequencing 
In order to sequence purified PCR products, sequencing reactions were 
performed using a Verity thermocycler (Applied Biosystems) and the Applied 
Biosystems BigDye® Terminator v1.1 Cycle Sequencing Kit. Forward and 
reverse primers have been used in different reaction. 
 
Table 21. Sequencing reaction protocol. 
Step Action 
1 Combine the following elements into a 0.2 ml tube: 
 5x Sequencing Buffer (5µl) 
 BigDye® Terminator v1.1 Ready Reaction 
Mix (4µl) 
 DMSO (2µl) 
 Primer 10 µM (1µl) 
 DMSO (2µl) 
 Molecular biology pure water 24.(6µl) 
 cDNA (2µl) 
Sample 
preparation 





 95°C for 5 minutes 
 25-step cycle: 
95°C for 30 seconds 
50°C for 10 seconds 
60°C for 4 minutes 
 Store at 4°C 
 
The purified sequencing reaction product was added to formamide in a 1:1 
ratio and denatured by heat shock (95°C for three minutes). The sample was 
ready for separation by capillary electrophoresis in an automatic sequencer 
ABI Prism 310 (Applied Biosystems, Foster City, CA). 
 
5.13 - Cytokine and Chemokine ELISA assays 
Twelve pro-inflammatory cytokines (Multi-Analyte ELISArray™ TLR-induced 
Viral Cytokines, SABiosciences, Frederick, MD) were analyzed using a 
conventional ELISA protocol under uniform conditions. The following 
cytokines and chemokines were comprised in the array: TNFα, IL1b, IL6, 
IL12, IL17A, IL8, MCP-1, RANTES, IP-10, MIG, TARC, and IFNa. Four 
additional cytokines were analyzed individually: IL10, IL4, GM-CSF, TGFß1. 
Incubation with liquid samples allows the capture antibodies to bind the 
specific protein of interest. After washing unbound proteins, cytokine-specific 
biotinylated antibodies added to the wells did bind the captured analyte. After 
washing, an avidin-horseradish peroxidase conjugate is added. Wells were 
washed again and a colorimetric substrate solution was added, which 
produced a blue color in direct proportion to the amount of analyte present in 
the initial sample. Color development was stopped by the stop solution. OD 
values were read at 450 nm. The following controls were included: a) 
negative control wells incubated with plain cell culture medium; b) positive 
control wells incubated with known amounts of reference cytokines; c) cell 
culture medium from uninfected HeLa cell cultures; d) cell culture medium 





for 48 hrs); e) cell culture medium from HeLa cell cultures exposed to PV 
obtained from PPS patients (0.1 ml undiluted medium) or from HeLa cell 
cultures exposed to HEVs obtained from T1D patients (0.1 ml undiluted 
medium). 
 
Table 22. ELISArray protocol. 
Step Action 
1 Prepare all reagents. Set up experimental samples, 






2 Add 50 µl of assay buffer into each well of the plate. 
Transfer 50 µl of samples and control samples into the 
appropriate well and incubate for 2h. 
3 Wash three times with PBS. 
4 Add 100 µl of Detection Antibody solution and incubate 
for 1h. Detection 
antibody 
conjugation 
5 Wash three times with PBS. 
6 Add 100 µl of Avidin – HRP. Incubate 30 minutes. 
7 Wash four times with PBS, 
8 Add 100 µl of Development Solution. Incubate 15 
minutes in the dark. 
Analyze 
9 Add 100 µl of Stop Solution and read OD 450nm within 
30 minutes. 
 
5.14 – T1D patients` database 
In order to organize the ever increasing data collected over the last few years, 
a specific database of T1D patients has been developed. Data is stored into a 
mySQL database, and a PHP interface allows to insert and modify data 
directly from an internet browser. Different levels of permission are designed 
for reading and writing into the database and users are organized as 





The database has the ability to collect general data (age, sex, date of 
admission) as well as clinical data (pancreatic autoantibodies, glucose, C-
peptide, HbA1c, HLA type). Demographic information and epidemiological 
data were organized and integrated into Google world maps. Sensible data is 
cryptographed on the client-side with a specific Java application. 
Automated data analysis is performed and organized in chart, thanks to the 






5.13 - Figures 
 
Figure 9 Virus amplification by cell culture. 1, 2) Leukocytes are collected from whole blood samples and 3) are co-cultured with HeLa cells. 







Figure 10. HEVs 3D amplification method. A) HEV 3D region tree. B) From the classical five-group organization, a seven group subdivision 








Figure 11. PCR primers. 
 
In the PPS study, an original three-primer pairs method was designed. We have added to our 
previous panPolio 3D primer-set three new primers with high affinity for the three serotypes 
3D region. A more general HEV PCR-detection method was designed for the viral RNA 
polymerase amplification. Basing on a complete HEVs alignment of the 3D region, a 






Figure 12. PVs-specific primer pairs against the 3D genomic region. 
 











Figure 13. HEVs-specific primer set against the 3D genomic region.  
 













6 – Results 
 
6.1 – Type 1 Diabetes 
Samples from 112 T1D children aged 2 to 18 years have been investigated 
for the presence of HEV genomes in blood at the time of clinical onset. HeLa 
cells were co-cultured with leukocytes in order to amplify the virus load. After 
five consecutive passages, a quota of supernatant was analyzed. Two 
different cohorts were investigated: a 90-children group from Varese, Italy 
(years 2005-2010) and a 22-children group from Pisa, Italy (years 2005-
2010). To organize this increasing amount of data (demographic information, 
date of diagnosis, pancreatic autoantibodies, glucose, C-peptide, HbA1c, 
HLA type) a specific database has been developed. Tissue culture, viral 
protein expression, and gene amplification of conserved genomic regions 
were used for virus detection. Three different methods were used to 
investigate virus persistence: 
 Amplification methods based on the 5‘UTR genomic region; 
 A patented and validated method based on the capsidic VP1 region; 
 A novel original method based on the 3D region coding for the viral 
RNA polymerase. 
A total of 69 samples were used as controls, including relatives (n=37), blood 
donors (n=20) and pediatric healty controls (children admitted to our Pediatric 
ward for minor traumatic lesions n=12). 
Temporal and geographic clusters of T1D cases were observed in different 
years. In 13 different cases, samples have been obtained from consenting 






Table 23. T1D Patients details. 
Years Country Locality 
Patients 
Relatives 
No. Mean Age 
2005-2010 Italy Varese 90 9,32 29 
2005-2010 Italy Pisa 22 7,63 8 
Total 112 8,95 37 
 







































6.1.1 – PCR and real-time PCR results 
In a first phase of the study, HEVs genome fragments have been investigated 
with a real-time PCR approach. We chose this method because it is fast and 
provides quantitative information on virus levels. 
The target region of the real-time PCR is a conserved domain in the 5‘UTR 
fragment. Then we realized that this did not give satisfactory results, since the 
method was not sensitive enough. 
 
Table 24. PCR and real-time PCR results. 
 5’ UTR 3D polymerase 
Patients (n) 28% positive (n=64) – 
Years 2005-2010 
80% positive (n=112) – 
Years 2005-2010 






When patient samples were analyzed with the highly sensitive 3D method, 
5‘UTR results were confirmed and the percentage of positive samples was 
sensibly increased. Moreover, the 3D method can discriminate between 
seven subgroups of HEVs, providing some information about virus serotype. 
Thanks to these results, a temporal and geographic epidemiologic analysis 
can be inferred. 
 
Figure 16. T1D positive patients HEV species and 3D group distribution. A) Overall 
distribution (n=112). B) Varese cohort distribution (n=90) vs. Pisa cohort distribution (n=22). 























































































6.1.2 – Family cases 
Over the past few years, a number of 13 families with at least one member 
with T1D were analyzed for HEV infections. A total of 51 subjects were 
investigated. Clinical (autoantibodies, HbA1, C-pept) and epidemiological 
data (temporal and geographic associations of cases) were collected. In most 
cases, HEVs positivity was also found in family members (first degree 
relatives of diabetic children). In positive-families, the same HEV type was 
detected. In a few cases (2 families), double positivity for two different viral 
species and 3D groups was detected. Interestingly, during a short period of 






In two different families (GG and UG), two consecutive T1D cases were 
observed. In the UG family, the T1D patient‘s sister developed diabetes nine 
month after her brother. In the GG family, GN patient developed diabetes 14 
month after his brother. 
 
6.1.3 – Temporal and geographic epidemiologic analysis 
A temporal and geographic epidemiologic study was performed on subjects 
from the Varese cohort (n=90). 
 














































Based on the T1D onset, seasonality of the Varese cohort was deduced 
(Figure 17). Assuming that enterovirus infection occurred at least 3 months 
before clinical onset, infection seasonality was transposed of 3 months. At 
T1D onset, the HbA1 values were already high implying that high glucose 
values had been present for at least 2-3 months before onset. According to 
our data, cases of T1D in the Varese cohort are concentrated in the months 
of October-December. Supposedly, HEV infections peaked in summer 
months. Cases were grouped into clusters occurring within a 5 km radius in a 






6.1.4 – Virus protein expression by IIF in cell lines exposed to 
leukocytes of T1D patients 
Immunofluorescence tests were made in human HeLa and AV3 cell lines as 
well as in mouse HPL3.4 cells co-cultured with leukocytes obtained from 
peripheral blood samples of T1D patients at onset. Expression of viral 
proteins was evaluated using commercial monoclonal antibodies directed to 
capsid epitopes common to HEVs (Table 10). Immunofluorescence results 
obtained with HeLa, AV3, and HPL 3.4 cells were comparable. As positive 
controls, HeLa, AV3 and HPL 3.4 cells were infected at low m.o.i. with PV-1 
CHAT strain or CVB4. Since most clear IIF results were obtained with the 
AV3 cell line, these cells have been used in subsequent experiments. 





Table 25) all but one samples positive by PCR for HEV genome, were also 
positive for capsid antigen expression. In the family GG, positive results were 
obtained in all family members. The GG brother, who developed T1D several 
months later, was already positive by IIF at the time of testing. Similar results 
were observed in the UG family. The T1D patient‘s sister developed T1D nine 
month later, but was already positive by IIF and PCR at the time of testing. 
Surprisingly, the BTS family resulted negative by IIF, but positive by PCR 
(Figure 20). This may be interpreted as a lack of reactivity of panenterovirus 






Table 25 T1D Families comparative results. 
 Patient IIF PCR 
Family GG 
GG Father + + 
GG Mother + + 
GG T1D Patient + + 
GG Brother + + 
Family SC 
SC Father - - 
SC T1D Patient + + 
SC Brother + + 
Family BTS 
BTS Father - + 
BTS Mother - + 
BTS T1D Patient - + 
Family UG 
UG Father - - 
UG Mother + - 
UG T1D Patient + + 







Figure 18. IIF of GG Family. A) GG Father. B) GG Mother. C) T1D patient. D) GG Brother. 
 
In the GG family, T1D patient‘s brother developed diabetes 14 month later. IIF positivity can be notice in T1D patient 
as well as the entire family. 
 
Figure 19. IIF of SC Family. A) SC Father. B) T1D Patient. C) SC Brother. 
 





Figure 20. IIF of BTS Family. A) BTS Father. B) BTS Mother. C) T1D patient. 
 
No IIF can be notice from BTS T1D patient, as well as in the rest of the family. 
 
Figure 21. IIF of UG Family. A) UG Father. B) UG Mother. C) T1D Patient. D) UG Sister. 
 
Cytoplasmic IIF was detected in UG T1D patient as well as his sister and mother. No IIF in UG Father. UG Sister 
























































































BTS (patient) F 3,5 DR3 DR4 DQ2 DQ3 10,9 0,3-0,3 
50,6 >100 21 
  +     
BT (father BTS) F  DR3 DR4 DQ2   0,1 0,5 0,7 
  +     
BTA (mother BTS) M  DR3 DQ2   0,1 0,6 1 
  +     
DM 
DM (patient) M 
10 DR3 DQ2 14 0,3-0,4 23,1 100 >100 
   +    
DH (father DN) M  DR3 DR5 DQ2 DQ5   0,1 0,3 0,6 
       
DF (mother DH) F  DR3 DR10 DQ2 DQ5   0,1 0,4 0,6 
   +    
DA (brother DM) M  DR5 DR10 DQ5   0,1 0,5 0,7 
       
FA 
FA (patient) M 
9 DR3 DR6 DQ1 DQ6 12,2 0,3-0,3 >100 0,4 34 
    +   
FMas (father FA) M  DR6 DR16 DQ5 DQ6   0,1 0,3 0,8 
   + +   
FMat (brother FA) M  DR3 DR16 DQ2 DQ5   0,7 0,4 1,4 
    +   
FPA (mother FA) F  DR1 DR5 DQ2 DQ5   0,1 0,4 0,9 
   + +   
GG 
GG (patient) M 
5 DR4 DQ2 8 2,8-3 0,1 27 1,7 
 +      
GN (patient, brother GG) M 4 DR3 DR4 DQ2 7,6 0,3-0,5 0,5 0,2 3,7 
 +      
GV (father GG/GN) M  DR1 DRB3 DQ2 DQ5    0,1 0,2 0,6 
 +      
GCMC (mother GG/GN) F  DR4 DR 10 DQ2 DQ5   0,1 0,2 0,8 
 +      
HSG 
HSG (patient) M 
14 DR1 DR4 DQ3 DQ5  14 0,3-0,5 1,3 48,9 10,3 
   + +   
HY (sister HSG) F  DR1 DR4 DQ3 DQ5   ne ne ne 
   + +   
HF (father HSG) M  DR4 DQ3   ne ne ne 
   + +   
HRG (mother HSG) F  DR1 DR4 DQ3   ne ne ne 






LM (patient) F 8 DR1 DR4 DQ3 DQ5 10,7 1,39 ne ne ne 
+       
LN (father LM) M      ne ne ne 
+       
LB (sister LM) F      ne ne ne 
+       
MT 
MT (patient) F 
13 DR4 DR11 DQ3 16,8 0,3 ne ne ne 
   +    
MA (father MT) M  DR4 DR7 DQ2 DQ3   ne ne ne 
    +   
MR (sister MT) F  DR4 DR14 DQ3 DQ5   ne ne ne 
       
MMP (mother MT) F  DR11 DR14 DQ3 DQ5   ne ne ne 
    +   
MC 
MC (patient) F 6 DR2 DR5 DQ1 DQ3  14 0,3-0,4 62 6,8 13,4 
    +   
ML (sister MC) F  DR1 DR4 DQ3 DQ5   0,1 0,3 0,9 
    +   
MCN (brother MC) M  DR3 DR4   0,1 0,3 0,8 
    +   
MFB (mother MC) F  DR3 DR4 DQ2 DQ3    0,1 0,3 0,6 
       
PA 
PA (patient) M 16 DR3 DR4 DQ2 DQ3 14 0,09 ne ne ne 
    +   
PM (brother PA) M  DR3 DR7 DQ2   ne ne ne 
       
PA (sister PA) F  DR3 DQ2   ne ne ne 
       
PPF (father PA) M  DR3 DR7 DQ2 DQ7   ne ne ne 
    +   
PSG (mother PA) F  DR3 DR4 DQ2 DQ3   ne ne ne 
    +   
RM 
RM (patient) M 
6 DR3 DQ2 14 0,4-0,5 102 nd nd 
      + 
RA (twin sister RM) F  DR3 DR11 DQ2 DQ3   0,1 0,4 0,9 
       
RL (father RM) M  DR3 DR14 DQ2 DQ5   0,1 0,3 1 
       
RMR (mother RM) F  DR3 DR11 DQ2 DQ3   0,1 0,3 0,9 
       
SC 
SC (patient) M 14 DR3 DR4 DQ2 DQ3 16,6 1,6-2,1 9,8 31,2 0,7 
 +      
SM (father SC) M  DR3 DR13 DQ2 DQ3   0,1 0,2 0,9 
       
SA (brother SC) M  DR3 DR4 DQ2 DQ4   0,1 0,3 1 
 +      
SMT (mother SC) F  DR4 DQ3   0,1 0,3 0,7 






SM (patient) M 3 DR3 DR4 DQ2 DQ3 9,3 
<0,3-
<0,3 0,1 2,3 1 
  +     
SG (twin sister SM) F  DR3 DR16 DQ2 DQ5   0,1 0,2 1 
  +     
SG (father SC) M  DR3 DR4 DQ3 DQ5   0,1 0,2 0,8 
       
SSS (mother SC) F  DR4 DR16 DQ3 DQ5   nd nd nd 
       
UG 
UG (patient) F 
11 DR3 DR4 DQ2 DQ3 12,4 0,6-1,8 4,1 30,6 >100 
 +      
UM (patient, brother UG) M 9 DR3 DR4 DQ2 7,7 2,2-2,6 0,1 >100 >100 
 +      
UF (father UG) M   DR4 DR14 DQ3 DQ5   0,1 0,3 1 
       
UDBC (mother UG) F   DR3 DR11 DQ2 DQ3   0,1 0,5 0,6 
       





Figure 22. Temporal and geographic clustering of T1D cases. A) Distribution of family cases. B) Clusters of T1D cases in Sep-Dec 2005. C) 








6.1.5 – Cytokine and chemokine expression 
Cytokine expression was analyzed in supernatant of HeLa cells co-cultured 
with leukocytes from peripheral blood of T1D patients. After co-culture for one 
week, HeLa cells underwent 4-5 weekly passages by trypsinization and 
washing. At that time, it is expected that no more leukocytes were present in 
the cultures. The cytokine expression was tested in the supernatant of the 
above cultures (n = 19) in comparison to cultures treated in the same way 
with peripheral blood leukocytes (PBL) obtained from blood donors (n = 10; 
control group). Expression level is represented as fold over the control group. 
HeLa cells not exposed to leukocytes were used as background control for 
blood donors‘ data (n = 6). As reported for other epithelial cell types (Basolo 
et al., 1996), high levels of IL6 were observed in HeLa cells alone as well as 
in cultures exposed to blood donors` or patients` leukocytes. As a result, IL-6 
levels were not changed by exposure of HeLa cells to T1D patients` 
leukocytes (Figure 23). High levels of the MCP-1 chemokine were observed 






Figure 23. T1D patients cytokines and chemokines level. A) T1D patients citokines fold change over uninfected controls (n=19). B) HeLa 
















































































































































































































































Abbreviations: TNFa, tumor necrosis factor alpha; IL1B-IL12-IL17A-IL8-IL4-IL10, Interleukin ; MCP-1, Monocyte chemotactic protein-1; 
RANTES, regulated upon activation normal T-cell expressed, and presumably secreted; IP-10, Interferon-inducible protein-10; MIG, 
Monokine Induced by Interferon Gamma; TARC, Thymus and activation-regulated chemokine; IFNa, Interferon alpha; GM-CSF, granulocyte 






6.2 – The post-polio syndrome (PPS) 
During the past years, a number of different biological samples were collected 
from 65 patients with diagnosed post-polio syndrome. Cerebrospinal fluid 
(CSF), tissue samples, whole blood, saliva and urine from Varese district 
were investigated for HEVs. When available, blood samples from first-degree 
relatives were collected. 
A total of 61 samples were used as controls, including relatives (n=30), blood 
donors (n=20), and pathologic controls (neurologic patients with non-
infectious, autoimmune, or neoplastic disease; n=11). 
 
Table 27. Samples from PPS patients and controls. 
Specimen PPS samples Controls samples 
CSF 20 11 
Whole blood 60 50 
Saliva 3 3 
Urine 3 3 
Tissue (skeletal muscle, 
peripheral nerve, duodenal 
mucosa) 
3 4 
Total 89 (Patients no. = 65) 71 (Controls no. = 61) 
 
Since PVs tropism is specific for motor neurons, CSF samples were analyzed 
for HEV presence. Because of the difficulty to obtain this specimen, tests 
were made on a variety of samples. We chose to collect whole blood samples 
because it‘s simple to obtain and it appeared to have the same sensitivity of 
CSF for HEV detection. HeLa cells were co-cultured with peripheral blood 
leukocytes and after five consecutive passages, the supernatant was 
analyzed for enterovirus presence. 
 





An optimized PCR method was set up in order to detect PV genome 
fragments in PPS samples. Initially, a pan-polio primer pair directed against 
the 3D region was utilized to amplify genome fragments. Subsequently, 
amplicons were sequenced for identifying the PV type. Afterwards, the 
method was modified to discriminate between the three PV types. PV 
genome fragments and low-level infectivity have been detected in 55/65 
(84.6%) of PPS patients. 
 
Figure 24. PV detection in PPS patients by RT-PCR. A) Distribution of PV-positive patients 
positives vs. PV-negative patients (n=65). B) PV types detected by RT-PCR of the 3D region 





















The majority of PPS patients was positive for serotype 1 (n=40), whereas 
PV2 and PV3 serotypes were less frequent (n=6 and n=4 respectively). For 
the rest of the cases, viral fragments were not typable (n=5). PV genome 
fragments could be detected in only 2 of 58 control subjects (3.4 %). 
 
6.2.2 – Poliovirus sequencing 
A study was conducted in an attempt to sequence fragments of genomic 
poliovirus from PPS patients. Different regions were analyzed and sequenced 
with primers directed against the entire poliovirus genome. Attempts to 
sequence three different regions were performed: the 5‘UTR region, the VP1 
region, the 3D region. 
In particular, some patients were deeply investigated and extended fragments 





the genomic variability of viral RNA fragments exposed for decades to the 






Figure 25. Conservation of PV genome fragments in PPS patients. A) Conservation of the 5‘UTR region (nt 285-533; n=5). B) Conservation 






















































6.2.3 – Cytokine and chemokine expression 
As in the case of diabetes (Figure 18), cytokine expression was analyzed in 
the supernatant of HeLa cells co-cultured with leukocytes from peripheral 
blood of 29 PPS patients. Expression levels are represented as fold over 
controls (cell cultures exposed to peripheral leukocytes of blood donors; n = 
10). HeLa not exposed to human leukocytes were used as background 
control for the blood donors group (n=3). 
As shown in Figure 21, high levels of MCP-1 and IP-10 were observed in 
cultures exposed to leukocytes from PPS patients (up to 7 and 5 times, 







Figure 26. PPS patients cytokines and chemokines level. A) PPS patients citokines fold change over uninfected controls (n=29). B) HeLa 

























































































































































































































Abbreviations: TNFa, tumor necrosis factor alpha; IL1B-IL12-IL17A-IL8-IL4-IL10, Interleukin ; MCP-1, Monocyte chemotactic protein-1; 
RANTES, regulated upon activation normal T-cell expressed, and presumably secreted; IP-10, Interferon-inducible protein-10; MIG, 
Monokine Induced by Interferon Gamma; TARC, Thymus and activation-regulated chemokine; IFNa, Interferon alpha; GM-CSF, granulocyte 






6.3 – Viral cardiomyopathy 
A retrospective analysis of 12 archived tissues, 3 fresh samples from lethal 
cases of suspected myocarditis and three blood samples from subacute 
clinical cases was performed. The aim of the study was to ascertain whether 
HEV genomes could be detected. Archived cases were fixed in formalin and 
fresh tissues were taken post-mortem and frozen at -70°C. Peripheral blood 
leukocytes were separated from peripheral blood and co-cultured with HeLa 
cells (using the already reported protocol). After co-culture for one week, 
HeLa cells underwent 4-5 weekly passages by trypsinization and washing. 
 
Table 28. Viral cardiomyopathy samples. 
Sample # Age Sex Diagnosis 
Paraffin-fixed 
tissue 
1 3 M 
Acute inflammatory cardiomyopathy 
(fulminant myocarditis) with associated 
cardiogenic shock 
2 55 F Hypersensitivity myocarditis 
3 23 M Lymphocytic myocarditis 
4 18 F 
Inflammatory cardiomyopathy (dilated 
cardiomyopathy with myocarditis) 
5 11 F Fulminant lymphocytic myocarditis 
6 49 F Hypersensitivity myocarditis 
7 1 M Fulminant lymphocytic myocarditis 
8 66 M Giant cell myocarditis 
9 44 F Giant cell myocarditis 
10 2 F 
Inflammatory cardiomyopathy (dilated 
cardiomyopathy with lymphocytic and 
hystiocytic myocarditis) 
11 44 F Giant cell myocarditis 
12 52 M 
Dilated cardiomyopathy associated with 
hypersensitivity myocarditis 
Fresh tissue 
13 41 F Mild inflammatory changes 
14 58 F Fulminant lymphocytic myocarditis 







16 18 F Inflammatory cardiomyopathy 
17 51 M Subacute myocarditis 
18 31 M Inflammatory cardiomyopathy 
 
6.3.1 – PCR results 
HEV genome fragments have been investigated with a RT-PCR directed to 
conserved domains in the 5‘UTR region. Results were confirmed by three 
different primer-pairs (Table 16). Paraffin-fixed tissues from non-viral 
myocarditis (n=3), PBLs from blood donors (n=20) and autopsy tissues 
obtained form trauma-associated death (n=2) were used as controls. 
 



































































Five of the 12 lethal cases of myocarditis in paraffin-fixed samples were HEV 
positive. Previously, serological and cell culture methods failed to identify any 
infectious agents associated with the disease. Following the successful set up 
of a protocol for recovery viral RNA from autopsy specimens, molecular 





detection of viral genome and adverse cardiac events. Two of the three post-
mortem samples were also positive to the PCR test. Two of the 
myocardiopathy patients analyzed by RT-PCR on blood samples were HEV-
positive. This result was in agreement with the detection of HEV IgM and high 






7 – Summary of results  
In this work, different persistent viral infection models have been studied. In 
particular, we focused our attention on T1D, PPS, and viral cardiomyopathy. 
Traditionally, the diagnosis of enteroviral disease is based on the isolation of 
virus in cell culture. However this method is labor-intensive and requires at 
least 7 days for primary virus isolation and identification. For a negative 
report, 21 days are required in order to complete blind virus passages. A 
rapid diagnostic test might therefore have a strong impact on the 
management of patients with HEV infections, especially in light of the 
availability of novel antiviral drugs. Recently, PCR has been employed in 
rapid detection of viral sequences in a variety of tissues and bodily fluids, 
proving to be a sensitive and specific diagnostic tool. In particular, the newly 
developed PCR method, based on the conserved viral 3D region, was proven 
effective in revealing small quantities of viral genomes. Combined with our 
technique of biological amplification of virus, the RT-PCR method became 
more sensitive than when applied directly to non-cultured samples. 
The purpose of this study was to analyze the viral agents potentially 
associated with slowly progressing clinical syndromes. A number of different 
biological samples were investigated to correlate molecular findings with 
pathologic features and immunohistochemistry. While immunohistochemical 
methods allowed the detection, identification and enumeration of 
inflammatory cells within the specimens, PCR allowed the detection of viral 
agents even if present in minute amounts.  
 
7.1 – T1D discussion 
The analysis of over 100 T1D patients from two different cohorts has led to 
the detection of HEVs in over 80% of patients at clinical onset. HEVs of the B 
species were most frequently detected. Epidemiological and geographic data 
showed numerous clusters of cases especially in the last quarter of the year, 
supporting the hypothesis of a viral infection. In particular, in the Varese 





infections. Cases were, in fact, concentrated in the months of September-
December, whereas enterovirus infections appear to peak during summer 
(June-August). Based on HbA1c data, we can assume that hyperglycemia 
(and possibly infection) was present at least 2-3 month before clinical onset. 
Investigations of family cases supported the viral infection hypothesis, since 
intra-familial infections have been detected, but diabetes developed only in 
family members carrying the high-risk HLA haplotypes. In families where 
more than one case developed, the presence of virus in blood was detected 
in even in the patient‘s brother/sister before clinically overt diabetes 
developed. 
 
7.2 – PPS discussion 
In the PV persistence study, we found that 86% of PPS patients were positive 
for the presence of the viral genome, while CSF, PBLs and bioptic tissues 
from control patients were free from demonstrable PV sequences. It therefore 
appears that the PVs are capable of persisting in the body for years after the 
first contact with this pathogen (i.e., the acute attack of paralytic polio that 
occurred many decades before). It is still unknown whether the virus is 
present in patients who, despite having contracted acute paralytic 
poliomyelitis, failed to progress to PPS. So far, in fact, we were unable to 
study sufficient numbers of patients with ―stable polio‖ (i.e., non-progressing 
poliomyelitis). In the absence of predictive biomarkers, it is not possible to 
predict if and when a polio survivor will develop PPS. Moreover, some PPS 
cases can be attributed to aging or to concomitant pathologies. 
 
7.3 – Viral cardiomyopathy discussion 
The initial phase of this study is promising, since about two thirds of the three 
investigated patient groups were positive by PCR assays directed to the 
conserved 5`UTR region of HEVs. 
Since the true prevalence of mild myocarditis is clinically elusive (frequently 





molecular diagnostics will likely lead to clarify the etiology of this serious 






8 – Conclusions 
Taken together, the above data indicate that different HEV types can cause 
persistent infections in apparently normal subjects. These low-level infections 
are associated with different clinical syndromes affecting the endocrine, 
nervous, or cardiovascular system. 
Even if these data do not prove a causal relationship between HEV infections 
and diabetes, the high prevalence of HEV genome sequences, the observed 
clustering of some T1D cases, as well as familial HEV infections (in a few 
cases with diabetes developing in two siblings within a few months after 
infection), indicate that different HEV types represent a significant biomarker 
of juvenile diabetes. Positivity for HEV genomes was also associated with the 
expression of pancreatic autoantibodies. If comparable results could be 
obtained in patient cohorts from different geographic areas, HEV detection 
methods would contribute recognizing some of the environmental agents 
linked to diabetes. 
If a causal relationship between enterovirus infections and T1D were to be 
finally established, it would be interesting to evaluate the feasibility of an 
enterovirus vaccine for primary prevention of the disease. The efficiency of 
vaccination against poliovirus is an encouraging example. However, it will be 
necessary to have more information concerning the distribution of 
diabetogenic HEV types in different geographic areas.  
The study of PPS patients clearly showed that PVs can persist in the body for 
decades after the acute infection. Sequencing results showed that the 3D 
region (viral RNA polymerase) remains highly conserved. These results thus 
suggest that the 3D region may be used as a target both for diagnosis and for 
antiviral drugs. Further studies will allow to sequence the entire viral genome 
in a larger number of patients and to assess whether the changes observed 
so far are common to multiple persisting strains. The complete 
characterization of the genome may clarify the pathogenic mechanism by 
which the PVs can persist in vivo for decades. The consistent finding of PV 





the progressive degeneration of motor units. This view appears to open new 
avenues both for prevention and treatment of PPS. 
Sequencing data from our PPS study strongly suggest that the persisting 
HEVs detected in PPS and diabetes are highly mutated. In fact, most PV 
isolates obtained from PPS patients showed genetic alterations in the 
explored regions (5`UTR and VP1) that probably are affecting the ability of 
virus to replicate and its antigenic properties. Even these strains, however, 
show some residual infectivity in the sense that they remain present in the 
body for long periods of time (decades in PPS) and are still able – when 
propagated at low levels in cell cultures – to express structural proteins and to 
induce the production of specific cytokines. From the genetic standpoint, 
these viruses are known to undergo two main types of genetic variations, 
namely mutations and recombination events (Agol, 2006; Yang et al., 2005; 
Vignuzzi et al., 2005). 
Finally, our results on viral myocardiopathy emphasize the relevance of newer 
molecular tools for elucidating the etiopathogenesis of this clinical condition. 
Further myocardiopathy cases will be undoubtedly investigated using the 
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